



NCDR[®]

NATIONAL CARDIOVASCULAR DATA REGISTRY

Published Manuscripts Based on NCDR Registries

Published Registry Manuscripts Table of Contents (TOC)

Legend	3
CARE Registry [®]	5
PUBLISHED.....	5
CathPCI Registry [®]	7
PUBLISHED.....	7
IN PRESS.....	23
Chest Pain-MI Registry [®]	23
PUBLISHED.....	23
IN PRESS	32
Diabetes Collaborative Registry Publications.....	32
PUBLISHED.....	32
IN PRESS	33
ICD Registry™	33
PUBLISHED.....	33
IN PRESS	40
IMPACT Registry [®]	41
PUBLISHED	41
IN PRESS	42
LAAO Registry.....	42
PUBLISHED.....	42
PINNACLE Registry [®]	43
PUBLISHED.....	43
IN PRESS	46
PVI Registry.....	47
PUBLISHED.....	47
IN PRESS.....	47

TVT Registry.....	47
PUBLISHED.....	47
IN PRESS	51
NCDR-wide Publications.....	52
PUBLISHED.....	52
IN PRESS	52

NCDR[®] Registry Manuscripts

Legend

Manuscript Status is designated as follows:

- **Published/Full Citation Provided:** Manuscript is in print.
- **In Press:** Manuscript accepted for publication but has not yet appeared in print or on-line.

Abbreviations:

- **Am J Cardiol:** American Journal of Cardiology
- **Am J Emerg Med:** American Journal of Emergency Medicine
- **Am J Medicine:** American Journal of Medicine
- **Am Heart J:** American Heart Journal
- **Br Med J:** British Medical Journal
- **Catheter Cardiovasc Interv:** Catheterization and Cardiovascular Interventions.
- **Circulation:** Circulation
- **Circ Arrhythm Electrophysiol:** Circulation: Arrhythmia and Electrophysiology
- **Circ Heart Fail:** Circulation: Heart Failure
- **Circ Interv:** Circulation: Cardiovascular Interventions
- **Circ Cardiovasc Imaging:** Circulation: Cardiovascular Imaging
- **Circulation: Cardiovasc Qual Outcomes:** Circulation: Cardiovascular Quality and Outcomes
- **Clin Cardiol:** Clinical Cardiology
- **Clin Med Res:** Clinical Medicine and Research
- **Eur Hear J:** European Heart Journal
- **Eur Hear J Quality Care Clinical Outcomes:** European Heart Journal: Quality of Care & Clinical Outcomes
- **Heart Rhythm:** Heart Rhythm
- **JACC:** Journal of the American College of Cardiology
- **JACC Cardiovasc Interv:** Journal of the American College of Cardiology: Cardiovascular Interventions
- **JACC Imaging:** Journal of the American College of Cardiology: Cardiovascular Imaging
- **JAHA:** Journal of the American Heart Association
- **JAMA:** Journal of the American Medical Association
- **JAMA Cardiol:** Journal of the American Medical Association: Cardiology

- ▯ **JAMA Int Med:** Journal of the American Medical Association: Internal Medicine
- ▯ **J Cardiovasc Manag:** The Journal of Cardiovascular Management (Pub ended 2005)
- ▯ **J Cardiovasc Electrophysiol:** Journal of Cardiovascular Electrophysiology
- ▯ **J Invas Cardiol:** Journal of Invasive Cardiology
- ▯ **Journal Biomed Inform:** Journal of Biomedical Informatics
- ▯ **J Cardiovasc. Manag:** Journal of Cardiovascular Management
- ▯ **NEJM:** New England Journal of Medicine
- ▯ **Pharmacoepidemiol Drug Saf:** Pharmacoepidemiology and Drug Safety

PUBLISHED

1. **53C.** Aronow HD, Kennedy KF, Wayangankar SA, et al. Prescription of Guideline-Based Medical Therapies at Discharge After Carotid Artery Stenting and Endarterectomy: An NCDR Analysis. *Stroke*. 2016;47(9).
2. **25C-A.** Giri J, Yeh RW, Kennedy KF, et al. Unprotected carotid artery stenting in modern practice. *Catheter Cardiovasc Interv*. 2014;83:595–602.
3. **19C.** Hynes BG, Kennedy KF, Ruggiero NJ, et al. Carotid Artery Stenting for Recurrent Carotid Artery Restenosis After Previous Ipsilateral Carotid Artery Endarterectomy or Stenting: A Report from the National Cardiovascular Data Registry. *JACC Cardiovasc Interv*. 2014;7(2):180-6.
4. **25C-B.** Giri J, Kennedy KF, Weinberg I, et al. Comparative Effectiveness of Commonly Used Devices for Carotid Artery Stenting an NCDR Analysis (National Cardiovascular Data Registry). *JACC Cardiovasc Interv*. 2014;7(2):171-7.
5. **01C.** Gruberg L, Jeremias A, Rundback JH, et al. Impact of glomerular filtration rate on clinical outcomes following carotid artery revascularization in 11,832 patients from the CARE registry. *Catheter Cardiovasc Interv*. 2014;84(2).
6. **48C.** Wimmer NJ, Spertus JA, Kennedy KF, et al. Clinical Prediction Model Suitable for Assessing Hospital Quality for Patients Undergoing Carotid Endarterectomy. *JAHA*. 2014;3(3).
7. **15C-B.** Rajamani K, Kennedy KF, Ruggiero NJ, et al. Outcomes of Carotid Endarterectomy in the Elderly: Report from the National Cardiovascular Data Registry. *Stroke*. 2013;44(4):1172-4.
8. **24C.** Wayangankar SA, Abu-Fadel MS, Aronow HD, et al. Hemorrhagic and Ischemic Outcomes After Bivalirudin Versus Unfractionated Heparin During Carotid Artery Stenting: A Propensity Score Analysis From the NCDR. *Circ Interv*. 2013;6(2).
9. **22C.** Mercado N, Cohen DJ, Spertus JA, et al. Carotid artery stenting of a contralateral occlusion and in-hospital outcomes: results from the CARE (Carotid Artery Revascularization and Endarterectomy) registry. *JACC Cardiovasc Interv*. 2013;6(1):59-64.
10. **32C.** Hawkins BM, Kennedy KF, Giri J, et al. Pre-procedural Risk Quantification for Carotid Stenting Using the CAS Score: A Report From the NCDR CARE Registry. *JACC*. 2012;60(17):1617-22.
11. **11C-A.** Don CW, House J, White C, et al. Carotid revascularization immediately before urgent cardiac surgery practice patterns associated with the choice of carotid artery stenting or endarterectomy: a report from the CARE (Carotid Artery Revascularization and Endarterectomy) registry. *JACC Cardiovasc Interv*.

12. **09C.** Yeh RW, Kennedy K, Spertus JA, et al. Do post marketing surveillance studies represent real- world populations? A comparison of patient characteristics and outcomes after carotid artery stenting. *Circulation*. 2011;123(13):1384-90.
13. **17C.** Longmore RB, Yeh RW, Kennedy KF, et al. Clinical Referral Patterns for Carotid Artery Stenting Versus Carotid Endarterectomy: Results from the Carotid Artery Revascularization and Endarterectomy Registry. *Circ Interv*. 2011;4:88-94
14. **13C.** Anderson HV, Rosenfield KA, White CJ, et al. Clinical features and outcomes of carotid artery stenting by clinical expert consensus criteria: a report from the CARE registry. *Catheter Cardiovasc Interv*. 2010;75(4):519-25.
15. **03C.** White CJ, Anderson HV, Brindis RG, et al. The Carotid Artery Revascularization and Endarterectomy (CARE) registry: objectives, design, and implications. *Catheter Cardiovasc Interv*. 2008;71(6):721-5.
16. **25C-C.** Giri J, Parikh SA, Kennedy KF, et al. Proximal Versus Distal Embolic Protection for Carotid Artery Stenting: A National Cardiovascular Data Registry Analysis. *JACC Cardiovasc Interv*. 2015;8:609-615.
17. **44C.** Hawkins BM, Kennedy KF, Yeh RW, et al. Hospital Variation in Carotid Stenting Outcomes. *JACC Cardiovasc Interv*. 2015;8(6):858-863.
18. **52C.** Wayangankar SA, Kennedy KF, Latif F, et al. Racial/Ethnic Variation in Carotid Artery Revascularization Utilization and Outcomes Analysis from the National Cardiovascular Data Registry. *Stroke*. 2015;46:1525-1532.

PUBLISHED

1. **106.** Valle JA, McCoy LA, Maddox TM, et al. Longitudinal Risk of Adverse Events in Patients with Acute Kidney Injury After Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry. *Circ Interv.* 2017;10(4).
2. **168.** Minges KE, Herrin J, Fiorilli PN, Curtis JP. Development and Validation of a Simple Risk Score to Predict 30-day Readmission After Percutaneous Coronary Intervention in a Cohort of Medicare Patients. *Catheterization and Cardiovascular Interventions.* 2017;89:955-963.
3. **289.** Acharya T, Salisbury AC, Spertus JA, et al. In-Hospital Outcomes of Percutaneous Coronary Intervention in America's Safety Net: Insights from the NCDR Cath-PCI Registry. *JACC Cardiovasc Interv.* 2017;10(15):1475-1485.
4. **305.** Fanaroff AC, Zakrofsky P, Dai D, et al. Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States. *JACC.* 2017;69(24):2913-2924.
5. **443P-A/168.** Minges KE, Herrin J, Fiorilli PN, et al. Development and Validation of a Simple Risk Score to Predict 30-day Readmission After Percutaneous Coronary Intervention in a Cohort of Medicare Patients. *Catheter Cardiovasc Interv.* 2017;89:955-963.
6. **300.** Jovin IS, Shah RM, Patel DB, et al. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated with Bivalirudin Versus Heparin: A Report from the National Cardiovascular Data Registry. *JACC Cardiovasc Interv.* 2017;10(11):1102-1111.
7. **106.** Valle JA, McCoy LA, Maddox TM, et al. Longitudinal Risk of Adverse Events in Patients with Acute Kidney Injury After Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry. *Circ Interv.* 2017;10(4).
8. **243.** Chui PW, Parzynski CS, Nallamothu BK, et al. Hospital Performance on PCI Process and Outcomes Measures. *JAHA.* 2017;6(5).
9. **196.** Doll JA, Dai D, Roe MT, et al. Assessment of Operator Variability in Risk-Standardized Mortality Following Percutaneous Coronary Intervention. *JACC Cardiovasc Interv.* 2017;10(7):672-682.
10. **244B.** Masoudi FA, Curtis JP, Desai NR, et al. PCI Appropriateness in New York. *JACC.* 2017;69(10):1243-1246.
11. **327.** Sapontis J, Marso SP, Cohen DJ, et al. The Outcomes, Patient Health Status, and Efficiency IN Chronic Total Occlusion Hybrid Procedures registry: rationale and design. *Coronary Artery Disease.* 2017;28(2):110-119.
12. **242.** Resnic FS, Majithia A, Marinac-Dabic D, et al. Registry-Based Prospective, Active Surveillance of Medical-Device Safety. *NEJM.* 2017;376:526-35.
13. **393P/156.** Amin AP, Patterson M, House JA, et al. Costs Associated with Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States. *JACC Cardiovasc Interv.* 2017;4:342-351.

14. **325.** Alnasser SM, Bagai A, Jolly SS, et al. Transradial approach for coronary angiography and intervention in the elderly: A meta-analysis of 777,841 patients. *International Journal of Cardiology*. 2017;228:45-51.
15. **367P.** Rymer JA, Harrison RW, Dai D, et al. Trends in Bare-Metal Stent Use in the United States in Patients Aged ≥ 65 Years (from the CathPCI Registry). *Am J Cardiol*. 2016;118(7):959-966.
16. **224.** Karrowni W, Vora AN, Dai D, et al. Blood Transfusion and the Risk of Acute Kidney Injury Among Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. *Circ Interv*. 2016;9(9).
17. **466P.** Motivala AA, Parikh V, Roe M, et al. Predictors, Trends, and Outcomes (Among Older Patients >65 Years of Age) Associated with Beta-Blocker Use in Patients with Stable Angina Undergoing Elective Percutaneous Coronary Intervention Insights from the NCDR Registry. *JACC Cardiovasc Interv*. 2016;9(16):1639-1648.
18. **468P.** Baber U, Giustino G, Wang T, et al. Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry. *Coronary Artery Disease*. 2016;27(6):442-448.
19. **272.** Schulman-Marcus J, Feldman DN, Rao SV, et al. Characteristics of Patients Undergoing Cardiac Catheterization Before Noncardiac Surgery: A Report from the National Cardiovascular Data Registry CathPCI Registry. *JAMA Int Med*. 2016;176(5):611-618.
20. **212.** Vora AN, Dai D, Gurm H, et al. Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention a Report from the National Cardiovascular Data Registry's CathPCI Registry. *Circ Interv*. 2016;9(3).
21. **354P.** Vora AN, Peterson ED, McCoy LA, et al. The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry CathPCI Registry. *JACC Cardiovasc Interv*. 2016;9(8):771-779.
22. **286P.** Kohsaka S, Miyata H, Ueda I, et al. An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-KiCS). *Am Heart J*. 2015;170(6):1077-1085.
23. **365P.** Anderson L, Dai D, Miller AL, et al. Percutaneous Coronary Intervention for Older Adults Who Present with Syncope and Coronary Artery Disease. Insights from the National Cardiovascular Data Registry®. *Am Heart J*. 2016;176:1-9.
24. **502P.** Wimmer NJ, Secemsky EA, Mauri L, et al. Effectiveness of Arterial Closure Devices for Preventing Complications with Percutaneous Coronary Intervention: An Instrumental Variable Analysis. *Circ Interv*. 2016;9(4).
25. **270P.** Wang TY, McCoy LA, Bhatt DL, et al. Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction. *Am Heart J*. 2016;172:9-18.
26. **394P.** Safley DM, Venkitachalam L, Kennedy KF, et al. Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights from the National Cardiovascular Data Registry. *JACC Cardiovasc Interv*. 2015;8(12):1574-1582.

27. **467P.** Wang TY, Grines C, Ortega R, et al. Women in Interventional Cardiology: Update in Percutaneous Coronary Intervention Practice Patterns and Outcomes of Female Operators from the National Cardiovascular Data Registry. *Catheter Cardiovasc Interv.* 2015;9(8).
28. **535P.** Sandhu A, McCoy LA, Negi SI, et al. Utilization of Mechanical Circulatory Support in Patients Undergoing Percutaneous Coronary Intervention: Insights From the NCDR. *Circulation.* 2015;137(5).
29. **421P.** Thomas MP, Parzynski CS, Curtis JP, et al. Percutaneous Coronary Intervention Utilization and Appropriateness across the United States. *PLOS ONE.* 2015;10(9).
30. **437P.** Boyden TF, Joynt KE, McCoy L, et al. Collaborative quality improvement vs public reporting for percutaneous coronary intervention: A comparison of percutaneous coronary intervention in New York vs Michigan. *Am Heart J.* 2015;170:1227-1233.
31. **504P.** Kadakia MB, Desai NR, Alexander KP, et al. Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted with Myocardial Infarction. *JACC Cardiovasc Interv.* 2015;3(11):1166-1177.
32. **521P.** Dasari TW, Saucedo JF, Krim S, et al. Clinical Characteristics and in-hospital Outcomes of Heart Transplant Recipients with Allograft Vasculopathy Undergoing Percutaneous Coronary Intervention: Insights from The National Cardiovascular Data Registry. *Am Heart J.* 2015;170(6):1086-1091.
33. **443P.** Desai NR, Bradley SM, Parzynski CS, et al. Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. *JAMA.* 2015;314(19):2045-2053.
34. **264.** Desai NR, Parzynski CS, Krumholz HM, et al. Patterns of Institutional Review of Percutaneous Coronary Intervention Appropriateness and the Effect on Quality of Care and Clinical Outcomes. *JAMA Int Med.* 2015;175(12):1988-90.
35. **334.** Dehmer GJ, Jennings J, Madden RA, et al. The National Cardiovascular Data Registry Voluntary Public Reporting Program: An Interim Report From the NCDR Public Reporting Advisory Group. *JACC.* 2016;67(2):205-215.
36. **534P.** Wayangankar SA, Bangalore S, McCoy LA, et al. Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report from the CathPCI Registry. *JACC Cardiovasc Interv.* 2016;9(4):341-351.
37. **378P.** Fiorilli PN, Mingos KE, Curtis JP, et al. Association of Physician Certification in Interventional Cardiology with In-Hospital Outcomes of Percutaneous Coronary Intervention. *Circulation.* 2015;132(19):1816-1824.
38. **253P-A:** Brennan JM, Sketch MH, Dai D, et al. Safety and Clinical Effectiveness of Drug-Eluting Stents for Saphenous Vein Graft Stenting in Older Individuals: Results from the Medicare-linked National Cardiovascular Data Registry® CathPCI Registry® (2005-2009). 2016;87(1):43-49.
39. **403P.** Aragam KG, Dai D, Gurm H, et al. Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing Percutaneous Coronary Intervention in the United States. *JACC.* 2015;65:2079–88.

40. **351P.** Cavender MA, Joynt KE, Parzynski CS, et al. State Mandated Public Reporting and Outcomes of Percutaneous Coronary Intervention in the United States. *Am J Cardiol.* 2015;115:1494-1501.
41. **356P-C:** Hess CN, Krucoff MW, Rao SV, et al. Comparison of quality-of-life measures after radial versus femoral artery access for cardiac catheterization in women: Results of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women quality-of-life sub study. *Am Heart J.* 2015;170(2):371-379.
42. **448P:** Swaminathan RV, Rao SV, McCoy LA, et al. Hospital Length of Stay and Clinical Outcomes in Older STEMI Patients After Primary PCI A Report from the National Cardiovascular Data Registry. *JACC.* 2015;65(12):1161–71.
43. **346P:** Spertus JA, Decker C, Gialde E, et al. Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: prospective cohort study before and after implementation of personalized bleeding risks. *Br Med J.* 2015;350.
44. **253P-B:** Brennan JM, Al-Hejily W, Dai D, et al. Three-Year Outcomes Associated With Embolic Protection in Saphenous Vein Graft Intervention Results in 49 325 Senior Patients in the Medicare-Linked National Cardiovascular Data Registry CathPCI Registry. *Circ Cardiovasc Interv.* 2015;8(3).
45. **447P.** Brilakis ES, Banerjee S, Karpaliotis D, et al. Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention a Report from the NCDR (National Cardiovascular Data Registry). *JACC Cardiovasc Interv.* 2015;8(2).
46. **405P.** Aronow HD, Gurm HS, Blankenship JC, et al. Middle-of-the-Night Percutaneous Coronary Intervention and its Association with Percutaneous Coronary Intervention Outcomes Performed the Following Day: An Analysis from the National Cardiovascular Data Registry. *JACC Cardiovasc Interv.* 2015;8:49–56.
47. **215P-M.** Anstrom KJ, Brennan JM, Eisenstein EL, et al. Examination of the Treatment Selection Process in a Multicenter Observational Study. *Circ Cardiovasc Qual Outcomes.* 2014;7:764-769.
48. **315P-B.** Nallamothu BK, Normand SLT, Wang Y, et al. Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study. *The Lancet.* 2015;385(9973):1114-1122.
49. **336P-B.** Zhang Z, Kolm P, Grau-Sepulveda MV, et al. Cost-Effectiveness of Revascularization Strategies: The ASCERT Study. *JACC.* 2015;65:1–11.
50. **372P.** Tsai TT, Patel UD, Chang TI, et al. Validated Contemporary Risk Model of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights from the National Cardiovascular Data Registry Cath-PCI Registry. *JAHA.* 2014;3(6).
51. **362P.** Sherwood MW, Brennan MJ, Ho KK, et al. The Impact of Extreme-Risk Cases on Hospitals' Risk-Adjusted Percutaneous Coronary Intervention Mortality Ratings. *JACC Cardiovasc Interv.* 2015;8(1):10-16.
52. **341P-B.** Hess CN, Rao SV, McCoy LA, et al. Identification of Hospital Outliers in Bleeding Complications After Percutaneous Coronary Intervention. *Circ Cardiovasc Qual Outcomes.* 2015;11(1).

53. **318P.** Yeh RW, Czarny MJ, Normand ST, et al. Evaluating the Generalizability of a Large Streamlined Cardiovascular Trial: Comparing Hospitals and Patients in the Dual Antiplatelet Therapy Study Versus the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes*. 2015;8(1):96-102.
54. **386P.** Bradley SM, Spertus JA, Kennedy, KF et al. Patient Selection for Diagnostic Coronary Angiography and Hospital-Level Percutaneous Coronary Intervention Appropriateness: Insights from the National Cardiovascular Data Registry. *JAMA Int Med*. 2014;174(10):1630-1639.
55. **356P-B.** Rao SV, Hess CN, Barham B, et al. A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention: The SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) Trial. *JACC Cardiovasc Interv*. 2014;7(8):857-867.
56. **452P.** Bradley SM, Rao SV, Curtis JP, et al. Change in Hospital-Level Use of Transradial Percutaneous Coronary Intervention and Periprocedural Outcomes: Insights from the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes*. 2014;7(4).
57. **398P.** Hess CN, Peterson ED, Neely ML, et al. The Learning Curve for Transradial Percutaneous Coronary Intervention among Operators in the United States: A Study from the National Cardiovascular Data Registry. *Circulation*. 2014;129(22):2277-86.
58. **390P.** Patel MR, Dai D, Hernandez AF, et al. Prevalence and predictors of non-obstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. *Am Heart J*. 2014;167(6):846-852.
59. **317P.** Abdallah MS, Spertus JA, Nallamothu BK, et al. Symptoms and Angiographic Findings of Patients Undergoing Elective Coronary Angiography Without Prior Stress Testing. *Am J Cardiol*. 2014;114(3):348-354.
60. **382P.** Hess CN, Rao SV, Dai D, et al. Predicting target vessel revascularization in older patients undergoing percutaneous coronary intervention in the drug-eluting stent era. *Am Heart J*. 2014;167(4):576-584.
61. **357P.** Hawkins BM, McCoy LA, Neely M, et al. Impact of Academic Year Timing on PCI Outcomes at Training Institutions. *JACC*. 2014;63(10):1025-30.
62. **348P.** Sherwood MW, Wang Y, Curtis JP, et al. Patterns and Outcomes of Red Blood Cell Transfusion in Patients Undergoing Percutaneous Coronary Intervention. *JAMA*. 2014;311(8):836-843.
63. **375P-B.** Hess CN, McCoy LA, Duggirala HJ, et al. Sex-Based Differences in Outcomes After Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Report From TRANSLATE-ACS. *JAHA*. 2014;3(1).
64. **244P.** Gupta N, Kontos MC, Gupta A, et al. Characteristics and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Following Cardiac Arrest (from the NCDR). 2014;113(7):1087-1092.
65. **268P-A.** Tsai TT, Patel UD, Chang TI, et al. Contemporary Incidence, Predictors, and Outcomes of Acute

66. **241P.** Chin CT, Messenger JC, Dai D, et al. Comparison of percutaneous coronary intervention for previously treated versus de novo culprit lesions in acute myocardial infarction patients: insights from the National Cardiovascular Data Registry. *Am Heart J.* 2014;167(3):393-400.
67. **330P.** Chan PS, Rao SV, Bhatt DL, et al. Patient and Hospital Characteristics Associated with Inappropriate Percutaneous Coronary Interventions. *JACC.* 2013;62(24):2274-81.
68. **215P-F.** Kutcher MA, Brennan JM, Rao SV, et al. Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: A report from the national cardiovascular data registry. *Catheter Cardiovasc Interv.* 2014;83(2):171-181.
69. **327P.** Kontos MC, Wang Y, Chaudhry SI, et al. Lower Hospital Volume Is Associated With Higher In-Hospital Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment – Elevation Myocardial Infarction: A Report From the NCDR. *Circ Cardiovasc Qual Outcomes.* 2013;6(6):659-67.
70. **341P-A.** Rao S, McCoy L, Spertus J, et al. An Updated Bleeding Model to Predict the Risk of Post-Procedure Bleeding Among Patients Undergoing Percutaneous Coronary Intervention: A Report Using an Expanded Bleeding Definition From the National Cardiovascular Data Registry CathPCI Registry. *JACC Cardiovasc Interv.* 2013;6(6):897-904.
71. **315P-A.** Menees DS, Peterson ED, Wang Y, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. *NEJM.* 2013;369(10):901-9.
72. **356P-A.** Hess CN, Rao SV, Kong DF, et al. Embedding a randomized clinical trial into an ongoing registry infrastructure: Unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). *Am Heart J.* 2013;166(3):421-428.
73. **349P.** Payvar S, Kim S, Rao SV, et al. In-Hospital Outcomes of Percutaneous Coronary Interventions in Extremely Obese and Normal-Weight Patients: Findings From the NCDR (National Cardiovascular Data Registry). *JACC.* 2013;62(8):692–6.
74. **159P-B.** Borden WB, Spertus JA, Mushlin AI, et al. Antianginal Therapy Before Percutaneous Coronary Intervention. *Circ Interv.* 2013;6(4).
75. **368P.** Brennan JM, Curtis JP, Dai D, et al. Enhanced Mortality Risk Prediction With a Focus on High-Risk Percutaneous Coronary Intervention Results From 1,208,137 Procedures in the NCDR. *JACC Cardiovasc Interv.* 2013;6(8):790-799.
76. **280P.** Fazel R, Curtis J, Wang Y, et al. Determinants of fluoroscopy time for invasive coronary angiography and percutaneous coronary intervention: Insights from the NCDR®. *Catheter Cardiovasc Interv.* 2013;82(7):1091-1105.

77. **215P-P.** Shah BR, McCoy LA, Federspiel JJ, et al. Use of Stress Testing and Diagnostic Catheterization After Coronary Stenting Association of Site-Level Patterns with Patient Characteristics and Outcomes in 247,052 Medicare Beneficiaries. *JACC*. 2013;62(5):439-446.
78. **369P.** Feldman DN, Swaminathan RV, Kaltenbach LA, et al. Adoption of Radial Access and Comparison of Outcomes to Femoral Access in Percutaneous Coronary Intervention an Updated Report from the National Cardiovascular Data Registry (2007–2012). *Circulation*. 2013;127:2295-2306.
79. **215P-E.** Kumar RS, Douglas PS, Peterson ED, et al. Effect of Race and Ethnicity on Outcomes with Drug-Eluting and Bare Metal Stents Results in 423,965 Patients in the Linked National Cardiovascular Data Registry and Centers for Medicare & Medicaid Services Payer Databases. *Circulation*. 2013;127(13):1395-403.
80. **306P.** Daugherty SL, Thompson LE, Kim S, et al. Patterns of Use and Comparative Effectiveness of Bleeding Avoidance Strategies in Men and Women Following Percutaneous Coronary Interventions: An Observational Study from the National Cardiovascular Data Registry®. *JACC*. 2013;61(20):2070-2078.
81. **295P.** Chhatriwalla AK, Amin AP, Kennedy KF, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. *JAMA*. 2013;309(10):1022-9.
82. **446P.** Nallamothu BK, Spertus JA, Lansky AJ, et al. Comparison of Clinical Interpretation with Visual Assessment and Quantitative Coronary Angiography in Patients Undergoing Percutaneous Coronary Intervention in Contemporary Practice: The Assessing Angiography (A2) Project. *Circulation*. 2013;127(17):1793-1800.
83. **325P.** Swaminathan RV, Wang TY, Kaltenbach LA, et al. Non-System Reasons for Delay in Door- To-Balloon Time and Associated In-Hospital Mortality: A Report from the NCDR®. *JACC*. 2013;61(16):1688-1695.
84. **413P.** Moussa I, Hermann A, Messenger JC, et al. The NCDR CathPCI Registry: a US national perspective on care and outcomes for percutaneous coronary intervention. *Heart*. 2013;99(5):297-303.
85. **192P.** Harrison RW, Aggarwal A, Ou FS, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. *Am J Cardiol*. 2013;111(2):178-84.
86. **370P.** Baklanov DV, Kaltenbach LA, Marso SP, et al. The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). *JACC*. 2013;61(4):420-6.
87. **215P-D.** Hillegass WB, Patel MR, Klein LW, et al. Long-term outcomes of older diabetic patients after percutaneous coronary stenting in the United States: a report from the National Cardiovascular Data Registry, 2004 to 2008. *JACC*. 2012;60(22):2280-9.
88. **296P.** Dattilo PB, Prasad A, Honeycutt E, et al. Contemporary patterns of fractional flow reserve and intravascular ultrasound use among patients undergoing percutaneous coronary intervention in the United

States: insights from the National Cardiovascular Data Registry. *JACC*. 2012;60(22):2337-9.

89. **248P.** Parikh NI, Honeycutt EF, Roe MT, et al. Left and codominant coronary artery circulations are associated with higher in-hospital mortality among patients undergoing percutaneous coronary intervention for acute coronary syndromes: report From the National Cardiovascular Database Cath Percutaneous Coronary Intervention (CathPCI) Registry. *Circ Cardiovasc Qual Outcomes*. 2012;5(6):775-82.
90. **344P.** Dehmer GJ, Weaver D, Roe MT, et al. A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011. *JACC*. 2012;60(20):2017-31.
91. **215P-H.** Patel MR, Marso SP, Dai D, et al. Comparative effectiveness of drug-eluting versus bare-metal stents in elderly patients undergoing revascularization of chronic total coronary occlusions: results from the National Cardiovascular Data Registry, 2005-2008. 2012;5(10):1054-1061.
92. **215P-S.** Federspiel JJ, Mudrick DW, Shah BR, et al. Patterns and predictors of stress testing modality after percutaneous coronary stenting: data from the NCDR(®). *JACC Imaging*. 2012;5(10):969-80.
93. **215P-I.** Anderson ML, Peterson ED, Brennan JM, et al. Short- and long-term outcomes of coronary stenting in women versus men: results from the National Cardiovascular Data Registry Centers for Medicare & Medicaid services cohort. *Circulation*. 2012;126(18):2190-9.
94. **215P-O.** Mudrick DW, Shah BR, McCoy LA, et al. Patterns of stress testing and diagnostic catheterization after coronary stenting in 250,350 Medicare beneficiaries. *Circ Cardiovasc Imaging*. 2013;6(1):11-9.
95. **249P.** Curtis JP, Geary LL, Wang Y, et al. Development of 2 registry-based risk models suitable for characterizing hospital performance on 30-day all-cause mortality rates among patients undergoing percutaneous coronary intervention. *Circ Cardiovasc Qual Outcomes*. 2012;5(5):628-37.
96. **283P-B.** Rao SV, Dai D, Subherwal S, et al. Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. *JACC Cardiovasc Interv*. 2012;5(9):958-65.
97. **311P.** Amin AP, Spertus JA, Cohen DJ, et al. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. *Archives of Internal Medicine*. 2012;172(15):1145-52.
98. **010P.** Dodson JA, Wang Y, Chaudhry SI, et al. Bleeding-Avoidance Strategies and Outcomes in Patients >80 Years of Age With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the NCDR® CathPCI Registry®). *Am J Cardiol*. 2012;110(1):1-6.
99. **334P.** Tavaris DR, Wang Y, Jacobs S, et al. Bleeding and vascular complications at the femoral access site following percutaneous coronary intervention (PCI): an evaluation of hemostasis strategies. *Journal of Invasive Cardiology*. 2012;24(7):328-34.
100. **215P-Q.** Mudrick D, Kaltenbach LA, Shah B, et al. Downstream testing and subsequent procedures after

coronary computed tomographic angiography following coronary stenting in patients ≥ 65 years of age. *Am J Cardiol.* 2012;110(6):776-83.

101. **193P.** Owan TE, Roe MT, Messenger JC, et al. Contemporary use of adjunctive thrombectomy during primary percutaneous coronary intervention for ST-elevation myocardial infarction in the United States. *Catheter Cardiovasc Interv.* 2012;80(7):1173-80.
102. **283P-C.** Subherwal S, Peterson ED, Dai D, et al. Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. *JACC.* 2012;59(21):1861-9.
103. **331P.** Bradley SM, Chan PS, Spertus JA, et al. Hospital percutaneous coronary intervention appropriateness and in-hospital procedural outcomes: insights from the NCDR. *Circ Cardiovasc Qual Outcomes.* 2012;5(3):290-7.
104. **336P.** Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. *NEJM.* 2012;366(16):1467-76.
105. **335P.** Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. *Circulation.* 2012;125(12):1501-10.
106. **185P-A.** Cram P, House JA, Messenger JC, et al. Indications for percutaneous coronary interventions performed in US hospitals: a report from the NCDR®. *Am Heart J.* 2012;163(2):214-21.
107. **185P-B.** Cram P, House JA, Messenger JC, et al. Percutaneous coronary intervention outcomes in US hospitals with varying structural characteristics: analysis of the NCDR®. *Am Heart J.* 2012;163(2):222-9.
108. **215P-C.** Brennan JM, Dai D, Patel MR, et al. Characteristics and long-term outcomes of percutaneous revascularization of unprotected left main coronary artery stenosis in the United States: a report from the National Cardiovascular Data Registry, 2004 to 2008. *JACC.* 2012;59(7):648-54.
109. **252P.** Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. *JACC Cardiovasc Interv.* 2012;5(2):131-40.
110. **215P-L.** Brennan JM, Peterson ED, Messenger JC, et al. Linking the National Cardiovascular Data Registry CathPCI Registry with Medicare claims data: validation of a longitudinal cohort of elderly patients undergoing cardiac catheterization. *Circ Cardiovasc Qual Outcomes.* 2012;5(1):134-40.
111. **195P.** Resnic FS, Wang TY, Arora N, et al. Quantifying the learning curve in the use of a novel vascular closure device: an analysis of the NCDR (National Cardiovascular Data Registry) CathPCI registry. *JACC Cardiovasc Interv.* 2012;5(1):82-9.

112. **215P-G.** Wang TY, Masoudi FA, Messenger JC, et al. Percutaneous coronary intervention and drug-eluting stent use among patients ≥ 85 years of age in the United States. *JACC*. 2012;59(2):105-12.
113. **009P.** Curtis JP, Rathore SS, Wang Y, et al. Use and Effectiveness of Intra-Aortic Balloon Pumps Among Patients Undergoing High Risk Percutaneous Coronary Intervention: Insights from the CathPCI Registry. *Circ Cardiovasc Qual Outcomes*. 2012;5(1):21-30.
114. **233P.** Chin CT, Weintraub WS, Dai D, et al. Trends and predictors of length of stay after primary percutaneous coronary intervention: a report from the CathPCI registry. *Am Heart J*. 2011;162(6):1052-61.
115. **245P.** Stribling WK, Kontos MC, Abbate A, et al. Left circumflex occlusion in acute myocardial infarction (from the National Cardiovascular Data Registry). *Am J Cardiol*. 2011;108(7):959-63.
116. **290P.** Rao SV, Kaltenbach LA, Weintraub WS, et al. Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. *JAMA*. 2011;306(13):1461-7.
117. **183P-B.** Brilakis ES, Rao SV, Banerjee S, et al. Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. *JACC Cardiovasc Interv*. 2011;4(8):844-50.
118. **204P-B.** Douglas PS, Patel MR, Bailey SR, et al. Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography. *JACC*. 2011;58(8):801-9.
119. **184P.** Deyell MW, Buller CE, Miller LH, et al. Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. *Archives of Internal Medicine*. 2011;171(18):1636-43.
120. **215P-B.** Tsai TT, Messenger JC, Brennan JM, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. *JACC*. 2011;58(18):1859-69.
121. **247P.** Chan PS, Patel MR, Klein LW, et al. Appropriateness of percutaneous coronary intervention. *JAMA*. 2011;306(1):53-61.
122. **159P-A.** Borden WB, Redberg RF, Mushlin AI, et al. Patterns and Intensity of Medical Therapy in Patients Undergoing Percutaneous Coronary Intervention. *JAMA*. 2011;305(8):1882-1889.
123. **144P.** Burjonrappa SC, Varosy PD, Rao SV, et al. Survival of Patients Undergoing Rescue Percutaneous Coronary Intervention. *JACC Cardiovasc Interv*. 2011;4(1):42-50.
124. **174P.** Wang TY, Peterson ED, Ou FS, et al. Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary

intervention: A report from the National Cardiovascular Data Registry. *Am Heart J*. 2011;161(1):76-83.

125. **183P-A.** Brilakis ES, Wang TY, Rao SV, et al. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. *JACC Cardiovasc Interv*. 2010;3(10):1068-73.
126. **197P.** Maddox TM, Ho PM, Roe M, et al. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. *Circ Cardiovasc Qual Outcomes*. 2010;3(6):632-41.
127. **163P.** Krone RJ, Rao SV, Dai D, et al. Acceptance, Panic, and Partial Recovery: The Pattern of Usage of Drug-Eluting Stents After Introduction in the U.S. (A Report From the American College of Cardiology/National Cardiovascular Data Registry). *JACC Cardiovasc Interv*. 2010;3(9):903-910.
128. **040P.** Lin GA, Redberg RF, Anderson HV, et al. Impact of Changes in Clinical Practice Guidelines on Assessment of Quality of Care. *Medical Care*. 2010;48(8):733-738.
129. **261P.** Amin AP, Marso SP, Rao SV, et al. Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding. *Circ Cardiovasc Qual Outcomes*. 2010;3(4):358-65.
130. **226P.** Marso SP, Amin AP, House JA, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. *JAMA*. 2010;303(21):2156-64.
131. **178P.** Peterson ED, Dai D, DeLong ER, et al. Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results from 588,398 Procedures in the National Cardiovascular Data Registry. *JACC*. 2010;55(18):1923-1932.
132. **204P-A.** Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. *NEJM*. 2010;362(10):886-95.
133. **007P.** Cardarelli F, Bellasi A, Ou FS, et al. Combined Impact of Age and Estimated Glomerular Filtration Rate on In-Hospital Mortality After Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the American College of Cardiology National Cardiovascular Data Registry). *Am J Cardiol*. 2009;103(6):766-771.
134. **085P.** Cavender MA, Milford-Beland S, Roe MT, et al. Prevalence, predictors, and in-hospital outcome of non-infarct artery Intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results from the National Cardiovascular Data Registry (NCDR). *Am J Cardiol*. 2009;104:507–513.
135. **149P.** Aggarwal A, Dai D, Rumsfeld JS, et al. Incidence and Predictors of Stroke Associated with

Percutaneous Coronary Intervention. *Am J Cardiol.* 2009;104:349–353.

136. **092P.** Kutcher MA, Klein LW, Ou FS, et al. Percutaneous Coronary Interventions in Facilities without Cardiac Surgery On-Site: A Report from the National Cardiovascular Data Registry (NCDR). *JACC.* 2009;59:16-24.
137. **122P.** Grantham JA, Marso SP, Spertus J, et al. Chronic total occlusion angioplasty in the United States. *JACC Cardiovasc Interv.* 2009;2(6):479-486.
138. **124P.** Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry. *Circ Interv.* 2009;2:222-229.
139. **001P-A.** SS Rathore, JP Curtis, BK Nallamothu, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. *Br Med J.* 2009;338.
140. **130P.** Akhter N, Milford-Beland S, Roe MT, et al. Gender Differences Among Patients with Acute Coronary Syndromes (ACS) Undergoing Percutaneous Coronary Intervention (PCI) in the American College of Cardiology-National Cardiovascular Data Registry. *Am Heart J.* 2009;157:141-8.
141. **164P.** Mehta RH, Ou FS, Peterson ED, et al. Clinical Significance of Post-Procedural Thrombolysis in Myocardial Infarction Flow in Patients with Cardiogenic Shock Undergoing Primary Percutaneous Coronary Intervention. *JACC Cardiovasc Interv.* 2009;2(1):56-64.
142. **008P.** Kao J, Vicuna R, Rumsfeld J, et al. Effect of Insurance Status on Use of Drug-Eluting Stents versus Bare Metal Stents in Patients Undergoing Elective Percutaneous Coronary Intervention. *Am Heart J.* 2008;156(6):1133-1140.
143. **135P.** Dixon WC 4th, Wang TY, Dai D, et al. Anatomic Distribution of the Culprit Lesion in Patients with Non–ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. *JACC.* 2008;15(16):1347-1351.
144. **084P.** Rao SV, Ou FS, Wang TY, et al. Trends in the Prevalence and Outcomes of Radial and Femoral Approaches to Percutaneous Coronary Intervention. *JACC Cardiovasc Interv.* 2008;1:379-386.
145. **138P.** Singh M, Peterson ED, Milford-Beland S, et al. Validation of the Mayo clinic risk score for in-hospital mortality after percutaneous coronary interventions using the national cardiovascular data registry. *Circ Cardiovasc Interv.* 2008;1(1):36-44.
146. **083P.** Wang TY, Peterson ED, Dai D, et al. Patterns of Cardiac Marker Surveillance after Elective Percutaneous Coronary Intervention: Implications for the Use of Peri-procedural Myocardial Infarction as a Quality Metric. *JACC.* 2008;51:2068-2074.
147. **002P.** Chakrabarti A, Krumholz HM, Wang TY, et al. Time-to-reperfusion in patients undergoing

interhospital transfer for primary percutaneous coronary intervention in the U.S: an analysis of 2005 and 2006 data from the National Cardiovascular Data Registry. *Am J Cardiol.* 2008;51(25):2442-3.

148. **039P.** Brener SJ, Milford-Beland S, Roe MT, et al. Culprit-only or multi-vessel revascularization in patients with acute coronary syndromes; An ACC-NCDR report. *Am Heart J.* 2008;155:140-6.
149. **151P.** Wang TY, Peterson ED, Dai D, et al. Patterns of Cardiac Marker Surveillance After Elective Percutaneous Coronary Intervention and Implications for the Use of Periprocedural Myocardial Infarction as a Quality Metric: A Report From the National Cardiovascular Data Registry (NCDR). *JACC.* 2008;51(21):2068-2074.
150. **143P.** Aggarwal A, Dai D, Rumsfeld JS, et al. Impact of Home Warfarin Use on the Treatment and Outcomes of Patients Undergoing Percutaneous Coronary Intervention. *Am J Cardiol.* 2008;101:1413–1417.
151. **047P.** Shaw LJ, Shaw RE, Merz CN, et al. Impact of Ethnicity and Gender Differences on Angiographic Coronary Artery Disease Prevalence and In-Hospital Mortality in the American College of Cardiology National Cardiovascular Data Registry. *Circulation.* 2008;117;1787-1801.
152. **134P.** Ting HH, Roe MT, Gersh BJ, et al. Factors Associated with Off-label Use of Drug Eluting Stents in Patients with ST-elevation Myocardial Infarction. *Am J Cardiol.* 2008;101:286-292.
153. **087P.** Mehta SK, Frutkin AD, Milford-Beland S, et al. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry). *Am J Cardiol.* 2007;100(7):1114–1118.
154. **006P.** Anderson HV, Shaw RE, Brindis RG, et al. Risk-Adjusted Mortality Analysis of Percutaneous Coronary Interventions by American College of Cardiology/American Heart Association Guidelines Recommendations. *Am J Cardiol.* 2007;99:189–196.
155. **022P.** Dehmer GJ, Kutcher MA, Dey SK, et al. Frequency of Percutaneous Coronary Interventions at Facilities without On-Site Cardiac Surgical Backup—A Report from the American College of Cardiology–National Cardiovascular Data Registry (ACC-NCDR®). *Am J Cardiol.* 2007;99:329–332.
156. **037P.** Tavaris DR, Gallauresi B, Brindis RG. "Hemostatic Devices". Chapter in: *Medical Device Epidemiology and Surveillance.* John Wiley & Sons, Ltd. England 2007, pages 379-394.
157. **115P-C.** Tavaris DR, Gallauresi BA, Dey S, et al. Risk of local adverse events by gender following cardiac catheterization. *Pharmacoepidemiology and Drug Safety.* 2007;16:125–131.
158. **103P.** Rao SV, Shaw RE, Brindis RG, et al. Patterns and outcomes of drug-eluting coronary stent use in clinical practice. *Am Heart J.* 2006;152(2):321–6.
159. **030P.** Huang HW, Brent BN, Shaw RE. Trends in Percutaneous Versus Surgical Revascularization of Unprotected Left Main Coronary Stenosis in the Drug-Eluting Stent Era—A

160. **038P.** Krone RJ, Shaw RE, Klein LW, et al. Ad Hoc Percutaneous Coronary Intervention (PCI) in Patients with Stable Coronary Artery Disease—A Study of Prevalence, Safety, and Variation in Use from the American College of Cardiology—National Cardiovascular Data Registry. Catheter Cardiovasc Interv. 2006;68(5):696–703.
161. **098P.** Rao SV, Shaw RE, Brindis RG, et al. On- versus Off-Label Use of Drug-Eluting Coronary Stents in Clinical Practice: Report from the ACC-NCDR. Am J Cardiol. 2006;97(10):1478–1481.
162. **061P.** Brindis RG, Dehmer GJ. Continuous quality improvement in the cardiac catheterization laboratory - Are the benefits worth the cost and effort? Circulation. 2006;113(6):767–770.
163. **115P-B.** Tavaris DR, Dey S, Albrecht-Gallauresi B, et al. Risk of Local Adverse Events following Cardiac Catheterization by Hemostasis Device Use — Phase II. J Invas Cardiol. 2005;17:644–650.
164. **053P.** Klein LW, Shaw RE, Krone RJ, et al. Mortality after Emergent PCI in Cardiogenic Shock Secondary to Acute Myocardial Infarction and Usefulness of a Mortality Prediction Model. Am J Cardiol. 2005;96(1):35–41.
165. **158P.** Singh M, Peterson ED, Roe MT, et al. Trends in the Association between Age and In-Hospital Mortality Following PCI: National Cardiovascular Data Registry Experience. Circ Interv. 2018;11(1).
166. **215P-A.** Douglas PS, Patel MR, Bailey SR, et al. Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography. JACC. 2011;58(8):801-9.
167. **216P-B.** Tsai TT, Maddox TM, Roe MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA. 2009;302(22):2458-64.
168. **018P.** Anderson HV, Shaw RE, Brindis RG, et al. Relationship between procedure indications and outcomes of percutaneous coronary interventions by the American College of Cardiology/American Heart Association Task Force Guidelines. Circulation. 2005;112(18):2786–2791.
169. **073P-B.** Brindis RG, Fitzgerald S, Anderson HV, et al. The American College of Cardiology-National Cardiovascular Data Registry™ (ACC-NCDR™): Building a National Clinical Data Repository. JACC. 2001;37(8):2240–5.
170. **123P.** Frutkin AD, Lindsey JB, Mehta SK, et al. Drug-Eluting Stents and the Use of Percutaneous Coronary Intervention Among Patients with Class I Indications for Coronary Artery Bypass Surgery Undergoing Index Revascularization: Analysis from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2009;2(7):614–21.

171. **152P.** Kim MS, Wang TY, Dai D, et al. Association of previous coronary artery bypass graft surgery with door-to-balloon time and in-hospital outcomes: a report from the National Cardiovascular Data Registry (NCDR). *JACC.* 2008;52(20):1665-70.
172. **156P.** Nallamothu BK, Wang Y, Bradley EH, et al. Comparing hospital performance in door-to-balloon time between the Hospital Quality Alliance and the National Cardiovascular Data Registry. *JACC.* 2007;50(15):1517-9.
173. **227P.** Douglas PS, Brindis RG. President's page: a question of quality: why national benchmarking? *JACC.* 2006;47(5):1076-8.
174. **228P.** Habash-Bseiso DE, Rokey R, Berger CJ, et al. Accuracy of noninvasive ejection fraction measurement in a large community-based clinic. *Clin Med Res.* 2005;3(2):75-82.
175. **229P.** Matheny ME, Ohno-Machado L, Resnic FS. Discrimination and calibration of mortality risk prediction models in interventional cardiology. *Journal Biomed Inform.* 2005;38(5):367-75.
176. **114P.** Dehmer GJ, Elma M, Hewitt K, et al. Bringing Measurement and Management Science to the Cath Laboratory: The ACC-NCDR and the Cardiac Catheterization Laboratory Continuous Quality Improvement Toolkit. *J Cardiovasc Manag.* 2004;15(6):20–6.
177. **115P-A.** Tavris DR, Gallauresi BA, Lin B, et al. Risk of Local Adverse Events Following Cardiac Catheterization by Hemostasis Device Use and Gender. *J Invas Cardiol.* 2004;16(9):459-64.
178. **109P.** Dehmer GJ, Hirshfeld JW, Oetgen WJ, et al. CathKIT: Improving Quality in the Cardiac Catheterization Laboratory. *JACC.* 2004;43:893–9.
179. **117P.** Shaw RE, Anderson HV, Brindis RG, et al. Updated Risk-Adjustment Mortality Model Using the Complete 1.1 Dataset from the ACC-NCDR. *J Invas Cardiol.* 2003;15(10):578–580.
180. **049P.** Krone RJ, Shaw RE, Klein LW, et al. Evaluation of the American College of Cardiology/American Heart Association and the Society for Coronary Angiography and Interventions Lesion Classification System in the Current 'Stent Era' of Coronary Interventions. *Am J Cardiol.* 2003;92:389–394.
181. **066P.** Klein LW, Block P, Brindis RG, et al. Percutaneous Coronary Interventions in Octogenarians in the American College of Cardiology—National Cardiovascular Data Registry: Development of a Nomogram Predictive of In-Hospital Mortality. *JACC.* 2002;40(3):394–402.
182. **064P.** Shaw RE, Anderson HV, Brindis RG, et al. Development of a Risk Adjustment Mortality Model Using the American College of Cardiology—National Cardiovascular Data Registry Experience: 1998-2000. *JACC.* 2002;39(7):1104–1112.
183. **065P.** Anderson HV, Shaw RE, Brindis RG, et al. A Contemporary Overview of Percutaneous Coronary Interventions: The American College of Cardiology—National Cardiovascular Data Registry. *JACC.* 2002;39(7):1096–1103.

184. **073P-A.** Brindis RG, Fitzgerald S, Anderson HV, et al. The ACC-NCDR: Building a National Clinical Data Repository. *JACC*. 2001;37(8):2240–2245.
185. **118P.** Weintraub WS. Development of the American College of Cardiology National Cardiovascular Data Registry. *J Invas Cardiol*. 1998;10(8):489-491.
186. **448P.** Swaminathan RV, Rao SV, McCoy LA, et al. Hospital Length of Stay and Clinical Outcomes in Older STEMI Patients After Primary PCI A Report from the National Cardiovascular Data Registry. *JACC*. 2015;65(12):1161–71.
187. **168P-A/57.** Lichtman JH, Wang Y, Jones SB, et al. Age and sex differences in in-hospital complication rates and mortality after percutaneous coronary intervention procedures: Evidence from the NCDR®. *Am Heart J*. 2014;167(3):376-383.
188. **191P/65.** Wang TY, McCoy LA, Messenger JC, et al. Cardiac biomarker measurement after elective percutaneous coronary interventions in older patients: Insights from the National Cardiovascular Data Registry. *Am Heart J*. 2013;166(5):927-34.
189. **297P/116.** Baklanov DV, Kim S, Marso SP, et al. Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: analysis from the national cardiovascular data registry. *Circ Cardiovasc Interv*. 2013;6(4):347-53.
190. **336P-C/129-C.** Chakrabarti AK, Grau-Sepulveda MV, O'Brien S, et al. Angiographic validation of the American College of Cardiology Foundation-the Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies study. *Circ Cardiovasc Interv*. 2014;7(1):11-8.
191. **375P-A/149.** Chin CT, Wang, TY, Anstrom KJ, et al. Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. *Am Heart J*. 2011;162(5):844-851.
192. **248A.** Secemsky EA, Kirtane A, Bangalore S. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States; *JACC Cardiovasc Interv*. 2016;9(23):2376-2386.
193. **368.** Valle JA, Kaltenbach LA, Bradley SM, et al. Variation in the Adoption of Transradial Access for ST-Segment Elevation Myocardial Infarction: Insights from the NCDR CathPCI Registry. *JACC Cardiovasc Interv*. 2017;10(22):2242-2254.
194. **357.** Sukul D, Bhatt DL, Seth M, et al. Appropriateness and Outcomes of Percutaneous Coronary Intervention at Top-Ranked and Non-Ranked Hospitals in the United States of America. *JACC Cardiovasc Interv*. Available online November 2017. <https://doi.org/10.1016/j.jcin.2017.10.042>.
195. Washam JB, Kaltenbach LA, Wojdyla DM, et al. Anticoagulant Use Among Patients with End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the

National Cardiovascular Data Registry. *Circ Cardiovasc Interv.* 2018;11(2).

196. **399.** Badri M, Shapiro T, Wang Y, et al. Adoption of the transradial approach for percutaneous coronary intervention and rates of vascular complications following transfemoral procedures: Insights from NCDR. *Catheter Cardiovasc Interv.* 2018;1-7.
197. **303.** Washam JB, Kaltenbach LA, Wojdyla DM, et al. Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry. *Circ Cardiovasc Interv.* 2018;11:e005628.

IN PRESS

Chest Pain-MI Registry®

PUBLISHED

1. **148.** Neeland IJ, Das SR, Simon DN, et al. The obesity paradox, extreme obesity, and long-term outcomes in older adults with ST-segment elevation myocardial infarction: results from the NCDR. *Eur Heart J Quality Care Clinical Outcomes.* 2017;3(3):183-191.
2. **100.** Doll JA, Li S, Chiswell K, et al. Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. *Eur Heart J.* 2018;39(3):193-200.
3. **156.** Pandey A, Golwala H, Hall HM, et al. Association of US Centers for Medicare and Medicaid Services Hospital 30-day Risk-Standardized Readmission Metric with Care Quality and Outcomes After Acute Myocardial Infarction: Findings from the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines. *JAMA Cardiology.* 2017;2(7):723-731.
4. **104A/53** Miller AL, Simon D, Roe MT, et al. Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites with Acute Myocardial Infarction. *Am J Cardiol.* 2017;119(8):1127-1134.
5. **97B.** Pokorney SD, Miller AL, Chen AY, et al. Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients with Low Ejection Fraction After Myocardial Infarction. *Circulation.* 2017;135:38-47.
6. **123.** Roswell RO, Kunkes J, Chen AY, et al. Impact of Sex and Contact-to-Device Time on Clinical Outcomes in Acute ST-Segment Elevation Myocardial Infarction—Findings from the National Cardiovascular Data Registry. *JAMA.* 2017;6(1).
7. **137.** Fanaroff AC, Peterson ED, Chen AY, et al. Intensive Care Unit Utilization and Mortality Among Medicare Patients Hospitalized with Non-ST-Segment Elevation Myocardial Infarction. *JAMA Cardiology.* 2017;2(1):36-44.
8. **144.** Doll JA, Hellkamp AS, Goyal A, et al. Treatment, Outcomes, and Adherence to Medication

9. **129A/64.** Harrison RW, Simon D, Miller AL, et al. Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry. *Am Heart J*. 2016;178:95-101.
10. **85.** Pandey A, McGuire DK, de Lemos JA, et al. Revascularization Trends in Patients with Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting with Non-ST Elevation Myocardial Infarction: Insights from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR ACTION Registry-GWTG). *Circ Cardiovasc Qual Outcomes*. 2016;9:197-205.
11. **59.** Anstey DE, Li S, Thomas L, et al. Race and Sex Differences in Management and Outcomes of Patients After ST-Elevation and Non-ST-Elevation Myocardial Infarct: Results From the NCDR. *Clin Cardiol*. 2016;39(10):585-595.
12. **166.** McNamara RL, Kennedy KF, Cohen DJ, et al. Predicting In-Hospital Mortality in Patients with Acute Myocardial Infarction. *J Am Coll Cardiol*. 2016;68(6):626-635.
13. **127.** Fordyce CB, Wang TY, Chen AY, et al. Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction with and Without Out-of-Hospital Cardiac Arrest. *J Am Coll Cardiol*. 2016;67(17):1981-1990.
14. **94.** Hess CN, Hellkamp AS, Roe MT, et al. Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients with Non–ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. *JAHA*. 2016;5(3).
15. **111.** Faridi KF, Peterson ED, McCoy LA, et al. Timing of First Post-Discharge Follow-up and Medication Adherence After Acute Myocardial Infarction. *JAMA Cardiol*. 2016;1(2):147-155.
16. **96.** Vora AN, Peterson ED, Hellkamp AS, et al. Care Transitions After Acute Myocardial Infarction for Transferred-In Versus Direct-Arrival Patients. *Circ Cardiovasc Qual Outcomes*. 2016;9(2).
17. **82.** Shah RU, de Lemos JA, Wang TY, et al. Post-Hospital Outcomes of Patients With Acute Myocardial Infarction With Cardiogenic Shock Findings From the NCDR. *JACC*. 2016;67(7):739-747.
18. **171A-C/77.** Wang TY, Vora AN, Peng SA, et al. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients with Reduced Ejection Fraction After Acute Myocardial Infarction. *JAHA*. 2016;5(1).
19. **203A.** Pokorney SD, Miller AL, Chen AY, et al. Implantable Cardioverter-Defibrillator Use Among Medicare Patients with Low Ejection Fraction After Acute Myocardial Infarction. *JAMA*. 2015;313(24):2433-2440.
20. **172A-C/78.** Doll JA, Hellkamp A, Thomas L, et al. Effectiveness of cardiac rehabilitation among older patients after acute myocardial infarction. *Am Heart J*. 2015;170(5):855-864.
21. **172A/78.** Doll JA, Hellkamp A, Ho PM, et al. Participation in Cardiac Rehabilitation Programs Among Older Patients After Acute Myocardial Infarction. *JAMA Int Med*. 2015;175(10):1700-1702.
22. **183A/99.** Gruberg L, Hellkamp AS, Thomas LE, et al. The Association of Previous Revascularization with In-Hospital Outcomes in Acute Myocardial Infarction Patients: Results from the National Cardiovascular Data Registry. *JACC Cardiovasc Interv*. 2015;8(15):1954-1962.

23. **202A/95.** Goyal A, de Lemos JA, Peng SA, et al. Association of Patient Enrollment in Medicare Part D with Outcomes After Acute Myocardial Infarction. *Circ Cardiovasc Qual Outcomes*. 2015; 8(6):567-575.
24. **198A/93.** Dasari TW, Hamilton S, Chen AY, et al. Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR). *Am Heart J*. 2016;172:1-8.
25. **176A.** Paixao A, Enriquez JR, Wang TY, et al. Risk Factor Burden and Control at the Time of Admission in Patients with Acute Myocardial Infarction: Results from the NCDR. *Am Heart J*. 2015;170(1):173-179.
26. **173A/79.** Hess CN, Peterson ED, Peng SA, et al. Use and Outcomes of Triple Therapy Among Older Patients with Acute Myocardial Infarction and Atrial Fibrillation. *JACC*. 2015;66:616–27.
27. **114A.** Kontos MC, Scirica BM, Chen AY, et al. Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry. *Am Heart J*. 2015;169:515-522.
28. **176A/80.** Paixao ARM, Enriquez JR, Wang TY, et al. Risk Factor Burden and Control at the Time of Admission in Patients with Acute Myocardial Infarction: Results from the National Cardiovascular Data Registry. *Am Heart J*. 2015;170(1):173–179.
29. **115A/58.** Kontos MC, Rennyson SL, Chen AY, et al. The association of myocardial infarction process of care measures and in-hospital mortality: A report from the NCDR®. *Am Heart J*. 2014;168(5):766-775.
30. **147A/72.** Karrow W, Wang TY, Chen AY, et al. Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients. *Heart*. 2015;101:264-270.
31. **123A/63.** Rousan TA, Pappay RM, Chen AY, et al. Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR). *Am J Cardiol*. 2014;114(8):1136-1144.
32. **160A/75.** Bagai A, Wang Y, Wang TY, et al. In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights Into Contemporary Practice From the National Cardiovascular Data Registry. *Circ Interv*. 2014;7:577-584.
33. **130A/65.** Hall HM, de Lemos JA, Enriquez JR, et al. Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States: Results From the National Cardiovascular Data Registry (NCDR). *Circ Cardiovasc Qual Outcomes*. 2018;11(1).
34. **110A/56.** Udell JA, Wang TY, Li S, et al. Clinical Trial Participation After Myocardial Infarction in a National Cardiovascular Data Registry. *JAMA*. 2014;312(8):841-843.
35. **132A/66.** Rao KK, Enriquez JR, de Lemos JA, et al. Use of aldosterone antagonists at discharge after myocardial infarction: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry–Get with the Guidelines (GWTG). *American Heart Journal*. 2013;166(4):709-715.
36. **029A/15.** Wang TY, Magid DJ, Ting HH, et al. The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. *Am Heart J*. 2014;167(6):833-839.
37. **144A/70.** Beatty AL, Li S, Thomas L, et al. Trends in Referral to Cardiac Rehabilitation After Myocardial

Infarction: Data from the National Cardiovascular Data Registry 2007 to 2012. JACC. 2014;63(23):2582-2583.

38. **074A/43.** McNamara RL, Chung SC, Jernberg T, et al. International Comparisons of the Management of Patients with Non-ST Segment Elevation Acute Myocardial Infarction in the United Kingdom, Sweden, and the United States: The MINAP/NICOR, SWEDEHEART/RIKS-HIA, and ACTION Registry-GWTG/NCDR Registries. International Journal of Cardiology. 2014;175:240-247.
39. **134A/67.** Shen L, Shah BR, Nam A, et al. Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. Am Heart J. 2014;167(6):840-845.
40. **085A/47.** Xian Y, Chen AY, Thomas L, et al. Sources of Hospital-Level Variation in Major Bleeding Among Patients with Non-ST-Segment Elevation Myocardial Infarction: A Report from the National Cardiovascular Data Registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014;7(2):236-243.
41. **151A/73.** Mumma BE, Kontos MC, Peng SA, et al. Association Between Prehospital ECG Use and Patient Home Distance from the PCI Center on Total Reperfusion Time in STEMI Patients: A Retrospective Analysis from the NCDR. Am Heart J. 2014;167(6):915-920.
42. **065A/35.** Sherwood MW, Wiviott SW, Peng SA, et al. Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights from the National Cardiovascular Data Registry. JAMA. 2014;3(2).
43. **050A.** Gupta N, Washam JB, Mountantonakis SE, et al. Characteristics, Management, and Outcomes of Cocaine-Positive Patients With Acute Coronary Syndrome (from the National Cardiovascular Data Registry). The American Journal of Cardiology. 2014;113(5):749-756.
44. **139A/68.** Harskamp RE, Wang TY, Bhatt DL, et al. Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. Am Heart J. 2014;167(3):355-362.
45. **145A/71.** Waldo WS, Brenner DA, Li S, et al. Reperfusion times and in-hospital outcomes among patients with an isolated posterior myocardial infarction: Insights from the National Cardiovascular Data Registry (NCDR). Am Heart J. 2014;167:350-354.
46. **120A/62.** Patel JH, Gupta R, Roe MT, et al. Influence of Presenting Electrocardiographic Findings on the Treatment and Outcomes of Patients with Non-ST-Elevation Myocardial Infarction. Am J Cardiol. 2014;113(2):256–261.
47. **119A/61.** Anderson ML, Peterson ED, Peng AS, et al. Differences in the Profile, Treatment, and Prognosis of Patients with Cardiogenic Shock by Myocardial Infarction Classification: A Report from National Cardiovascular Drug Registry. Circ Cardiovasc Qual Outcomes. 2013;6(6):7018-715.
48. **028A/14.** Desai NB, Peterson ED, Chen AY, et al. Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients – A report from the National Cardiovascular Data Registry. Am Heart J. 2013;166(6):1043-1049.
49. **73A/42.** Peacock WF, Kontos MC, Amsterdam E, et al. Impact of Society of Cardiovascular Patient Care Accreditation on Quality: An Action Registry®-Get with the Guidelines™ Analysis. Critical Pathways in Cardiology. 2013;12(3):116-120.
50. **101A/51.** Acharjee S, Roe MT, Amsterdam EA, et al. Relation of Admission High-Density Lipoprotein Cholesterol Level and In-Hospital Mortality in Patients with Acute Non-ST Segment

Elevation Myocardial Infarction (from the National Cardiovascular Data Registry). *Am J Cardiol.* 2013;112(8):1057-1062.

51. **90A/48.** Diercks BD, Kontos, MC, Hollander JE, et al. ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: Results from the NCDR. *Am J Emerg Med.* 2013;31(7):1005-1011.
52. **025A/12.** Scirica BM, Kadakia MB, de Lemos JA, et al. Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction: A Report from the ACTION Registry(R)-GWTG™. *Clinical Chemistry.* 2013;59(8):1205-1214.
53. **067A/38.** Hanna EB, Alexander KP, Chen AY, et al. Characteristics and In-Hospital Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing an Invasive Strategy According to Hemoglobin Levels. *Am J Cardiol.* 2013;111(8):1099-1103.
54. **045A/25.** Mogabgab O, Wiviott SD, Antman EM, et al. Relation Between Time of Symptom Onset of ST-Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry. *Clin Cardiol.* 2013;36(4):222-227.
55. **100A.** Enriquez JR, de Lemos JA, Parikh SV, et al. Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. *Am Heart J.* 2013;165(1):43-9.
56. **106A/54.** Riley RF, Newby LK, Don CW, et al. Guidelines-based treatment of anemic STEMI patients: practice patterns and effects on in-hospital mortality: a retrospective analysis from the NCDR. *European Heart Journal: Acute Cardiovascular Care.* 2013;2(1):35-43.
57. **062A/34.** Vavalle JP, Lopes RD, Chen AY, et al. Hospital Length of Stay in Patients with Non-ST-segment Elevation Myocardial Infarction. *Am J Medicine.* 2012;125:1085-1094.
58. **109A/55.** Shah RV, Holmes D, Anderson M, et al. Risk of Heart Failure Complication During Hospitalization for Acute Myocardial Infarction in a Contemporary Population Insights from the National Cardiovascular Data ACTION Registry. *Circ Heart Fail.* 2012;5:693-702.
59. **077A/45.** Miller AL, Dib C, Li L, et al. Left Ventricular Ejection Fraction Assessment Among Patients with Acute Myocardial Infarction and Its Association with Hospital Quality of Care and Evidence-Based Therapy Use. *Circ Cardiovasc Qual Outcomes.* 2012;5(5):662-671.
60. **040A/22.** Lopes RD, Li L, Granger CB, et al. Atrial Fibrillation and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes. *Am J Medicine.* 2012;125:897-905.
61. **066A-B/37.** Hanna EB, Chen AY, Roe MT, et al. Characteristics and in-hospital outcomes of patients presenting with non-ST-segment elevation myocardial infarction found to have significant coronary artery disease on coronary angiography and managed medically: Stratification according to renal function. *Am Heart J.* 2012;164(1): 52-57.
62. **031A/17.** Maddox TM, Ho PM, Tsai TT, et al. Clopidogrel Use and Hospital Quality in Medically Managed Patients with Non-ST-Segment-Elevation Myocardial Infarction. *CIRC Cardiovasc Qual Outcomes.* 2012;5:523-531.
63. **060A.** Chin CT, Wang TY, Li S, et al. Comparison of the Prognostic Value of Peak Creatine Kinase-MB and Troponin Levels Among Patients with Acute Myocardial Infarction: A Report from the Acute Coronary Treatment and Intervention Outcomes Network Registry–Get with The Guidelines. *Clin Cardiol.* 2012;35(7):424-9.

64. **059A/31.** Piña IL, Cohen MG, Rodriguez CJ, et al. Differences in Treatment Patterns and Outcomes Between Hispanics and Infarction: Results from the NCDR ACTION Registry GWTG Non-Hispanic Whites Treated for ST-Segment Elevation Myocardial Infarction. *JACC*. 2012;59:630-631.
65. **039A/21.** Subherwal S, Peterson ED, Chen AY, et al. Admission International Normalized Ratio Levels, Early Treatment Strategies, and Major Bleeding Risk Among Non-ST-Segment–Elevation Myocardial Infarction Patients on Home Warfarin Therapy: Insights From the National Cardiovascular Data Registry. *CIRC*. 2012;125:1414-1423.
66. **046A/26.** Yeo KK, Li S, Amsterdam EA, et al. Comparison of Clinical Characteristics, Treatments and Outcomes of Patients With ST-Elevation Acute Myocardial Infarction with Versus Without New or Presumed New Left Bundle Branch Block (from NCDR®). *Am J Cardiol*. 2012;109(4):497-501.
67. **057A/29.** Fox CS, Muntner P, Chen AY, et al. Health Services and Outcomes Research Short-Term Outcomes of Acute Myocardial Infarction in Patients With Acute Kidney Injury A Report From the National Cardiovascular Data Registry. *Circulation*. 2012;125:497-504.
68. **061A.** Das SR, Alexander KP, Chen AY, et al. Impact of Body Weight and Extreme Obesity on the Presentation, Treatment, and In-Hospital Outcomes of 50,149 Patients With ST-Segment Elevation Myocardial Infarction: Results from the NCDR (National Cardiovascular Data Registry). *JACC*. 2011;58:2642-2650.
69. **011A/5.** Melloni C, Roe MT, Chen AY, et al. Use of Early Clopidogrel by Reperfusion Strategy Among Patients Presenting With ST-Segment Elevation Myocardial Infarction. *Circ Cardiovasc Qual Outcomes*. 2011;4(6):603-609.
70. **066A-A.** Hanna EB, Chen AY, Roe MT, et al. Characteristics and In-Hospital Outcomes of Patients with Non-ST-Segment Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. *JACC Cardiovasc Interv*. 2011;4(9):1002-8.
71. **069A/40.** Wiviott SD, Saucedo JF, Antman EM, et al. Use of Emergency Medical Service Transport Among Patients With ST-Segment–Elevation Myocardial Infarction Findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry–Get with the Guidelines. *Circulation*. 2011;124:154-163.
72. **038A.** Wang TY, Nallamothu BK, Krumholz HM, et al. Association of Door-In-Door-Out Time with Reperfusion Delays and Outcomes Among Patients Transferred for Primary Percutaneous Coronary Intervention. *JAMA*. 2011;305(24):3540-3547.
73. **019A/8.** Abtahian F, Olenchock B, Ou FS, et al. Effect of prior stroke on the use of evidence- based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). *Am J Cardiol*. 2011;107(10):1441-1446.
74. **021A/10.** Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute β -blocker therapy: Results from the American College of Cardiology’s NCDR®. *Am Heart J*. 2011;161:864-870.
75. **055A.** Don CW, Roe, MT, Li S, et al. Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. *Am Heart J*. 2011;161(4):689-697.
76. **068A/39.** Britton KA, Aggarwal V, Chen AY, et al. No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. *Am Heart J*. 2011;161(4):657-663.

77. **071A/41.** Mathews R, Peterson ED, Chen AY, et al. In-Hospital Major Bleeding During ST-Elevation and Non-ST-Elevation Myocardial Infarction Care: Derivation and Validation of a Model from the ACTION Registry®-GWTG™. *Am J Cardiol.* 2011;107(8):1136-43.
78. **058A.** Chin CT, Chen AY, Wang TY, et al. Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. *Am Heart J.* 2011;161(1):113-122.
79. **084A/46.** Alexander, KP, Wang TY, Li S, et al. Randomized Trial of Targeted Performance Feedback to Facilitate Quality Improvement in Acute Myocardial Infarction Care. *Circ Cardiovasc Qual Outcomes.* 2011;4:129-135.
80. **022A/11.** Kontos MC, de Lemos JA, Ou FS, et al. Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with The Guidelines (NCDR ACTION-GWTG) Registry. *Am Heart J.* 2010;160(5):819-25.
81. **030A/16.** Kim MS, Wang TY, Ou FS, et al. Association of prior coronary artery bypass graft surgery with quality of care of patients with non-ST-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines. *Am Heart J.* 2010;160(5):951-7.
82. **036A/19.** Forman DE, Chen AY, Wiviott SD, et al. Comparison of outcomes in patients aged <75, 75 to 84, and ≥ 85 years with ST-elevation myocardial infarction (from the ACTION Registry- GWTG). *Am J Cardiol.* 2010;106(10):1382-8.
83. **044A-B/24.** Peterson ED, Roe MT, Chen AY, et al. The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. *Heart.* 2010;96(22):1798-802.
84. **020A/9.** Diercks DB, Owen KP, Kontos MC, et al. Gender differences in time to presentation for myocardial infarction before and after a national women's cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). *Am Heart J.* 2010;160(1):80-87.
85. **076A/44.** Roe MT, Messenger JC, Weintraub WS, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. *JACC.* 2010;56(4):254-63.
86. **007A/3.** Lopes RD, Peterson ED, Chen AY, et al. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. *JACC Cardiovasc Interv.* 2010;3(6):669-77.
87. **008A/4.** Glickman SW, Cairns CB, Chen AY, et al. Delays in fibrinolysis as primary reperfusion therapy for acute ST-segment elevation myocardial infarction. *Am Heart J.* 2010;159(6):998-1004.
88. **026A/13.** Kadakia MB, Desai NR, Alexander KP, et al. Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted with Myocardial Infarction: A Report from the NCDR ACTION Registry GWTG. *JACC Cardiovasc Interv.* 2010;3;1166-1177.

89. **017A/7.** Parikh SV, de Lemos JA, Jessen ME, et al. Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). *JACC Cardiovasc Interv.* 2010;3(4):419-27.
90. **012A/6.** Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. *Circulation.* 2010;121(3):357-65.
91. **044A-A/23.** Peterson ED, Roe MT, Rumsfeld JS, et al. A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction. *CIRC Cardiovasc Qual Outcomes.* 2009;2(5):491-9.
92. **006A/2.** Roe MT, Chen AY, Cannon CP, et al. Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients suppress Adverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries. *CIRC: Cardiovasc Qual Outcomes.* 2009;2(5):414-20.
93. **002A.** Diercks DB, Kontos MC, Chen AY, et al. Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. *JACC.* 2009;53(2):161-6.
94. **005A/1.** Cudnik MT, Frank Peacock W, Diercks DB, et al. Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients. *Clin Cardiol.* 2009;32(12):668-75.
95. **034A/18.** Leonardi S, Chen AY, Charachalou SM, et al. Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction. *Am Heart J.* 2012;164:502-8.
96. **49.** Mathews R, Fonarow GC, Li S, et al. Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with The Guidelines. *Am Heart J.* 2016;175:1-8.
97. **52.** Wayangankar SA, Roe MT, Chen AY, et al. Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy. *Indian Heart Journal.* 2016;68(4):464-472.
98. **117A/60.** McNamara RL, Wang Y, Partovian C, et al. Development of a Hospital Outcome Measure Intended for Use with Electronic Health Records: 30-Day Risk-standardized Mortality After Acute Myocardial Infarction. *Medical Care.* 2015;53:818-826.
99. **142A/69.** Enriquez JR, Lemos JA, Parikh SV et al. Modest Associations Between Electronic Health Record Use and Acute Myocardial Infarction Quality of Care and Outcomes. *Circ Cardiovasc Qual Outcomes.* 2015;8(6):576-585.
100. **159A/74.** Anderson LL, French WJ, Peng SA, et al. Direct Transfer from the Referring Hospitals to the

101. **166A/76.** Kang HJ, Simon D, Wang TY, et al. The Contemporary Use of Angiography and Revascularization Among Patients with Non-ST-Segment Elevation Myocardial Infarction in the United States Compared with South Korea. *Clin Cardiol.* 2015;38(12):708-714.
102. **83.** Sutton NR, Li S, Thomas L, et al. The Association of Left Ventricular Ejection Fraction with Clinical Outcomes after Myocardial Infarction: Findings from the ACTION Registry-GWTG Medicare Linked Database. *Am Heart J.* 2016;178:65-73.
103. **185 CERTS/131.** Vora AN, Wang TY, Hellkamp AS, et al. Differences in Short-and Long-Term Outcomes Among Older Patients with ST-Elevation Versus Non-ST-Elevation Myocardial Infarction with Angiographically Proven Coronary Artery Disease. *Circ Cardiovasc Qual Outcomes.* 2016; 9:513-522.
104. **118.** Vora AN, Wang TY, Li S, et al. Selection of Stent Type in Patients with Atrial Fibrillation Presenting with Acute Myocardial Infarction: An Analysis from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry—Get with the Guidelines. *JAHA.* 2017;6(8).
105. **137.** Yi Pi, Roe MT, Homes DN, et al. Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting (CABG) Trends in Patients with ST-elevation Myocardial Infarction: Results from the National Cardiovascular Data Registry ACTION Registry–GWTG. *Circ Cardiovasc Qual Outcomes.* 2017;10(8).
106. **238.** Pagidipati NJ, Hellkamp A, Thomas L. Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice. *JAMA Cardiol.* 2017;2(9):1040-1042.
107. **167.** Desai NR, Kennedy KF, Cohen DJ, et al. Contemporary risk model for in-hospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry - Get With The Guidelines (GWTG). *Am Heart J.* 2017;194(0):16-24.
108. **181.** Dharmarajan K, McNamara RL, Wang Y, et al. Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling. *Ann Intern Med.* 2017;167(8):555-564.
109. **134.** Smilowitz NR, Mahajan AM, Roe MT, et al. Mortality of Myocardial Infarction by Sex, Age, and Obstructive Coronary Artery Disease Status in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines). 2017;10(12):e003443.
110. **101.** Mody P, Wang T, McNamara R, et al. Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction. *Eur Hear J Quality Care Clinical Outcomes.* 2018;4(1):43-50.
111. **122.** Badri M, Abdelbaky A, Li S, et al. Percatheterization Use of P2Y12 Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry. *JAHA.* 2017;6(9).
112. **133.** Basra, S, Wang, T, Simon, D, et al. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. *Journal of the American Heart Association.* 2018.
113. **180.** Udell, J, Desai, N, Li, S, et al. Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. *Circulation: Cardiovascular Quality and Outcomes.* 2018.

114. **214.** Udell, J, Desai, N, Li, S, et al. Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. *Circulation: Cardiovascular Quality and Outcomes*. 2018.
115. **264.** Kini, V, Peterson, PN, Spertus, JA, et al Clinical Model to Predict 90-Day Risk of Readmission After Acute Myocardial Infarction. *Circ Cardiovasc Qual Outcomes*. 2018.
116. **265.** Wasfy, J, Kennedy, K, Masoudi, F et al. Predicting Length of Stay and the Need for Postacute Care After Acute Myocardial Infarction to Improve Healthcare Efficiency A Report From the National Cardiovascular Data Registry's ACTION Registry. *Circulation: Cardiovascular Quality and Outcomes*. 2018.

IN PRESS

1. **132.** Hansen, et al. Contemporary Pattern of Invasive Strategies for Patients with Non-ST elevation Myocardial Infarction: Insights from NCDR ACTION-GWTG. *JACC Cardiovasc Interv*.

Diabetes Collaborative Registry Publications

PUBLISHED

1. **4.** Fan, Wenjun, Yang Song, Silvio E. Inzucchi, Laurence Sperling, Christopher P. Cannon, Suzanne V. Arnold, Mikhail Kosiborod, and Nathan D. Wong. "Composite Cardiovascular Risk Factor Target Achievement and its Predictors in US Adults with Diabetes: The Diabetes Collaborative Registry." *Diabetes, Obesity and Metabolism* (2019).
2. **9.** Arnold SV, Inzucchi SE, Echouffo-Tcheugui JB, Tang F, Lam CSP, Sperling LS, Kosiborod M. Understanding Contemporary Use of Thiazolidinediones. An Analysis from the Diabetes Collaborative Registry. *Circ Heart Fail*. 2019;12
3. **20.** Arnold, SV; Lipska, KJ, Wang, J. et al. Use of Intensive Glycemic Management in Older Adults with Diabetes Mellitus. *Journal of the American Geriatrics Society*. (2018 Apr 10). Doi: 10.1111/jgs.15335.
4. **21.** Arnold SV, McGuire DK, Inzucchi SE, Tang F, Mehta SN, Lam CSP, Goyal A, Sperling LS, Wong ND, Hammar N, Fenici P, Kosiborod M. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). *J Diabetes Complications*. 2018.
5. **22.** Arnold, S.V.; Goyal, A.; Inzucchi, S.E. et al. Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry®. *Journal of the American Heart Association*. 2017; 6(8): <https://doi.org/10.1161/JAHA.117.005999>.
6. **23.** Arnold SV, Kosiborod M, Wang J, Fenici P, Gannedahl G, LoCasale RJ. Burden of cardio-renal/metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. *Diabetes Obes Metab*. 2018; 1–4. <https://doi.org/10.1111/dom.13303>.
7. **24.** Arnold SV, Echouffo-Tcheugui J, Lam CSP, Inzucchi SE, Tang F, McGuire DK, Goyal A, Maddox TM, Sperling LS, Fonarow GC, Masoudi FA, Kosiborod M. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). *Am Heart J*. 2018.
8. **26.** Arnold, S.V.; Inzucchi, S.E.; McGuire, D.K. et al. Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry.

Diabetes Care. 2016, Jul; 39(7): e99-e101.

9. **29.** Koehn D, Repetto E, Brookes-Smith I, et al. Second line glucose lowering treatment therapies as chosen by cardiologists vs non- cardiologists: an analysis of the Diabetes Collaborative Registry (DCR). EASD. 2018.
10. **N/A.** Arnold, SV; McGuire, DK; Inzucchi, SE, et al. Assessing the Use of Patient-Focused Pharmacotherapy in Glycemic Management Through the Diabetes Collaborative Registry (DCR). Journal of Diabetes and Its Complications. 2018 Aug 09.
11. **N/A.** Arnold, SV; Yap,J; Lam CSP, et al. Management of patients with diabetes and heart failure with reduced ejection fraction: an international comparison. Diabetes, Obesity and Metabolism. 2019 Feb;21(2):261-266. doi: 10.1111/dom.13511.

IN PRESS

ICD Registry™

PUBLISHED

1. **1.** Farmer SA, Kirkpatrick JN, Heidenreich PA, et al. Ethnic and racial disparities in cardiac resynchronization therapy. Heart Rhythm. 2009 Mar; 6(3):325-31.
2. **2.** Lampert R, Wang Y, Curtis J. Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data Registry (NCDR) Implantable Cardioverter/Defibrillator (ICD) Registry. Am Heart J. Feb 2013. 1015-1023.e2.
3. **3.** Peterson PN, Daugherty SL, Wang Y, et al. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. CIRC. 2009 Mar 3;119(8):1078-84.
4. **4.** Daugherty SL, Peterson PN, Wang Y, et al. Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria? Am Heart J. 2009 Aug;158(2):224-9.
5. **5.** Freeman JV, Wang Y, Curtis JP, et al. The Relation Between Hospital Procedure Volume and Complications of Cardioverter-Defibrillator Implantation From the Implantable Cardioverter-Defibrillator Registry Original Research Article. JACC. Volume 56, Issue 14, 28 September 2010, Pages 1133-1139.
6. **6.** Freeman JV, Wang Y, Curtis JP, et al. Physician Procedure Volume and Complications of Cardioverter-Defibrillator Implantation. CIRC 2012;125 57-64.
7. **7.** Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA. 2009 Apr 22;301(16):1661-70.
8. **8.** Al-Khatib SM, Hellkamp A, Curtis J, et al. Non-evidence-based ICD implantations in the United States. JAMA. 2011 Jan 5;305(1):43-9.
9. **9.** Al-Khatib SM, Hellkamp A, Bardy GH, et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA. 2013 Jan 2;309(1):55-62.
10. **10.** Al-Khatib S, Hellkamp A, Fonarow G, et al. Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. JAMA. 2014; 311(21):2209-2215.
11. **11.** Pun PH, Hellkamp AS, Sanders GD, et al. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. Nephrol. Dial. Transplant. (2014) doi: 10.1093/ndt/gfu274.

12. **12.** Zeitler EP, Hellkamp AS, Fonarow GC, et al. Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. *JCHF*. 2015; 3(2): 159-167.
13. **13.** Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients. Pokorney SD, Hellkamp AS, Yancy CW, et al. *Circ Arrhythmia Electrophysiol*. 2015; 8: 145-151.
14. **14.** Hess PL, Mi X, Curtis LH, et al. Follow-up of patients with new cardiovascular implantable electronic devices: Is adherence to the experts' recommendations associated with improved outcomes? *Heart Rhythm*. August 2013, Volume 10(8): 1127–1133. doi: 10.1016/j.hrthm.2013.06.009.
15. **15.** Hess PL, Hellkamp AS, Peterson ED, et al. Survival after Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients with Chronic Kidney Disease. *Circ Arrhythm Electrophysiol*. 2014; 7: 793-799.
16. **16.** Dewland TA, Pellegrini CN, Wang Y, et al. Dual-Chamber Implantable Cardioverter-Defibrillator Selection Is Associated With Increased Complication Rates and Mortality Among Patients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. *JACC*. Vol. 58, No. 10, 2011, 1007-1013.
17. **17.** Matlock DD, Peterson PN, Heidenreich PA, et al. Regional Variation in the Use of Implantable Cardioverter-Defibrillators for Primary Prevention : Results From the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes* 2011;4;114-121.
18. **18.** Aggarwal A, Wang Y, Rumsfeld JS, et al. Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation. *Heart Rhythm*. 2009 Nov;6(11):1565-71.
19. **19.** Tsai V, Goldstein MK, Hsia HH, et al. Age Differences in Primary Prevention Implantable Cardioverter-Defibrillator Use in U.S. Individuals. *J Am Geriatr Soc*. 2011 Sep;59(9):1589-95.
20. **20.** Matlock DD, Kutner JS, Emsermann CB, et al. Regional Variations in Physicians' Attitudes and Recommendations Surrounding Implantable Cardioverter-Defibrillators. *Journal of Cardiac Failure*. Volume 17, Issue 4, April 2011, Pages 318-324.
21. **21.** Schneider PM, Pellegrini CN, Wang Y et al. Prevalence of Guideline-Directed Medical Therapy Among Patients Receiving Cardiac Resynchronization Therapy Defibrillator Implantation in the National Cardiovascular Data Registry During the Years 2006 to 2008. *Am J Cardiol*. 2014 Jun 15;113(12):2052-6.
22. **22.** Fein AS, Wang Y, Curtis JP, et al. Prevalence and Predictors of Off-Label Use of Cardiac Resynchronization Therapy in Patients Enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry Original Research Article. *JACC*. Volume 56, Issue 10, 31 August 2010, Pages 766-773.
23. **23.** Ghanbari H, Nallamothu BK, Wang Y, and Curtis JP. Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR)®. *J Am Heart Assoc*. 2015; 4:e001331.
24. **24.** Haines DE, Wang Y, Curtis J. Implantable Cardioverter-Defibrillator Registry Risk Score Models for Acute Procedural Complications or Death After Implantable Cardioverter-Defibrillator Implantation. *CIRC*. 2011;123:2069-2076.
25. **25.** Hammill SC, Phurrough S, Brindis R. The National ICD Registry: Now and into the future. *Heart Rhythm*, Vol 3, No 4, April 2006; 471-473.
26. **26.** Hammill SC, Stevenson LW, Kadish AH, et al. Review of the Registry's First Year, Data Collected, and Future Plans. *Heart Rhythm*. September 2007; Vol. 4, Issue 9, Pages 1260-1263.
27. **27.** Hammill SC, Kremers MS, Stevenson LW, et al. Review of the Registry's Second Year, Data Collected, and Plans to Add Lead and Pediatric ICD Procedures. *Heart Rhythm*. September 2008; Vol. 5, Issue 9, Pages 1359-1363.
28. **28.** Kaiser DW, Tsai V, Heidenreich, PA, et al. Defibrillator Implantations for Primary Prevention in the United States: Inappropriate Care or Inadequate Documentation? Insights from the National Cardiovascular Data ICD Registry. *HRJ*. 2015.

29. **29.** Tsai V, Goldstein MK, Hsia HH, et al. Influence of Age on Perioperative Complications Among Patients Undergoing Implantable Cardioverter-Defibrillators for Primary Prevention in the United States. *Circ Cardiovasc Qual Outcomes*. 2011;4:549-556.
30. **30.** Cheng A, Wang Y, Curtis JP, Varosy PD. Acute lead dislodgements and in-hospital mortality in patients enrolled in the national cardiovascular data registry implantable cardioverter defibrillator registry. *J Am Coll Cardiol*. 2010 Nov 9;56(20):1651-6.
31. **31.** Farmer SA, Tuohy EJ, Small DS, et al. Impact of Community Wealth on Use of Cardiac-Resynchronization Therapy With Defibrillators for Heart Failure Patients. *Circ Cardiovasc Qual Outcomes*. 2012. Nov;5(6):798-807.
32. **32.** Cheng A, Wang Y, Berger RD et al. Electrophysiology Studies in Patients Undergoing ICD Implantation: Findings from the NCDR®. *Pacing Clin Electrophysiol*. 2012 Aug;35(8):912-8.
33. **33.** Wei S, Loyo-Berrios NI, Haigney MC, et al. Elevated B-Type Natriuretic Peptide Is Associated With Increased In-Hospital Mortality or Cardiac Arrest in Patients Undergoing Implantable Cardioverter-Defibrillator Implantation. *Circ Cardiovasc Qual Outcomes*. 2011 May;4(3):346-54.
34. **34.** Hammill SC, Kremers MS, Kadish AH, et al. Review of the ICD Registry's third year, expansion to include lead data and pediatric ICD procedures, and role for measuring performance. *Heart Rhythm*. 2009 Sep;6(9):1397-401.
35. **35.** Bhatt P, Curtis J, Wang Y, et al. Impact of a Recent Lead Recall on Utilization of Implantable Cardioverter Defibrillators: Data from the NCDR ICD Registry™. *J Cardiovasc Electrophysiol*. 2012 Aug;23(8):861-5.
36. **36.** Matlock DD, Peterson PN, Wang Y, et al. Variation in Use of Dual-Chamber Implantable Cardioverter-Defibrillators: Results From the National Cardiovascular Data Registry. *Arch Intern Med*. 2012;172(8):634-641.
37. **37.** Miller AL, Wang Y, Curtis J, et al. Optimal Medical Therapy Use Among Patients Receiving Implantable Cardioverter/Defibrillators: Insights From the National Cardiovascular Data Registry. *Arch Intern Med*. 2012 Jan 9;172(1):64-7.
38. **38.** Hammill SC, Kremers MS, Stevenson LW, et al. Review of the Registry's Fourth Year, Incorporating Lead Data and Pediatric ICD Procedures, and Use as a National Performance Measure Original Research Article. *Heart Rhythm*. 2010 Sep;7(9):1340-5.
39. **39.** Eapen ZJ, Al-Khatib S, Lopes RD, et al. Are Racial/Ethnic Gaps in the Use of Cardiac Resynchronization Therapy Narrowing?: An Analysis of 107,096 Patients From the National Cardiovascular Data Registry's ICD Registry. *J Am Coll Cardiol*. 2012 Oct 16;60(16):1577-8.
40. **40.** Dodson JA, Lampert R, Wang Y, et al. Temporal Trends in Quality of Care among ICD Recipients: Insights from the NCDR®. *Circulation*. 2013; published online before print November 5 2013, *Circulation*. 2014;129:580-586.
41. **41A.** Hsu JC, Varosy PD, Bao H, Wang Y, Curtis JP, Marcus, GM. Low Body Mass Index but Not Obesity is Associated with In-Hospital Adverse Events and Mortality Among Implantable Cardioverter-Defibrillator Recipients: Insights from the NCDR®. *J Am Heart Assoc*. 2012; 1: e003863 originally published October 30, 2012.
42. **41B.** Nishimura M, Marcus GM, Varosy PD, Bao H, Wang Y, Curtis JP, Hsu JC. Association of Body Mass Index with Cardiac Resynchronization Therapy Intention and Left Ventricular Lead Implantation Failure: Insights from the NCDR Implantable Cardioverter-Defibrillator Registry. *J Interv Card Electrophysiol*. 2019.
43. **42.** Russo AM, Wang Y, Al-Khatib SM, et al. Patient, Physician, and Procedural Factors Influencing the Use of Defibrillation Testing during Initial Implantable Cardioverter Defibrillator Insertion: Findings from the NCDR. *PACE* 2013 Aug 26. doi: 10.1111.
44. **43.** Hsu JC, Marcus GM, Al-Khatib SM, et al. Predictors of an Inadequate Defibrillation Safety Margin at

ICD Implantation. *J Am Coll Cardiol* 2014;64:256–64.

45. **44.** Akar JG, Bao H, Jones P, et al. Use of Remote Monitoring of Newly Implanted Cardioverter-Defibrillators: Insights from the Patient RElated Determinants of ICD Remote Monitoring (PREDICt RM) Study. *Circulation*. Originally published September 16, 2013. doi: 10.1161/CIRCULATIONAHA.113.002481.
46. **46.** Russo AM, Daugherty SL, Masoudi FA, et al. Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR). *Am Heart J*. 2015; 170 (2): 330-8.
47. **47.** Peterson PN, Varosy PD, Heidenreich PA, et al. Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. *JAMA*. 2013 May 15;309(19):2025-34.
48. **48.** Heidenreich PA, Tsai V, Curtis J, et al. A validated risk model for 1-year mortality after primary prevention implantable cardioverter defibrillator placement. *Am Heart J*. 2015; 170 (2): 281-289.e2.
49. **49.** Heidenreich PA, Tsai V, Bao H, et al. Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? *JACC HF*. 2015; 3(6): 497–504.
50. **50.** Prutkin JM, Reynolds MR, Bao H, et al. Rates of and Factors Associated with Infection in 200,909 Medicare Implantable Cardioverter-Defibrillator Implants: Results from the NCDR. *Circulation*, 2014;130:1037-1043.
51. **51.** Peterson PN, Greiner MA, Qualls LG, et al. QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. *JAMA*. 2013 Aug 14; 310(6):617-26. doi: 10.1001/jama.2013.8641.
52. **52.** Khazanie P, Hammill BG, Qualls LG, et al. Clinical Effectiveness of Cardiac Resynchronization Therapy vs Medical Therapy Alone Among Patients With Heart Failure: Analysis of the ICD Registry and ADHERE. *Circulation: Heart Failure*. 2014; 7: 926-934.
53. **53.** Kremers MS, Hammill SC, Berul CI, et al. The National ICD Registry Report: Version 2.1 including leads and pediatrics for years 2010 and 2011. *Heart Rhythm*. April 2013, Volume 10, Issue 4: Pages e59-e65.
54. **54.** Kramer DB, Kennedy KF, Noseworthy PA, et al. Characteristics and Outcomes of Patients Receiving New and Replacement Implantable Cardioverter-Defibrillators: Results From the NCDR. *Circ Cardiovasc Qual Outcomes*. 2013 July, 6(4): 488-497.
55. **55.** Steckman D, Varosy PD, Parzynski CS, et al. In-Hospital Complications Associated With Reoperations of Implantable Cardioverter Defibrillators. *American Journal of Cardiology*, Aug 1, 2014. 114(3): 419-426.
56. **57A.** Hsu JC, Varosy PD, Bao H, et al. Cardiac Perforation From Implantable Cardioverter-Defibrillator Lead Placement: Insights From the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes*. 2013; 6: 582-590.
57. **57B.** Hsu JC, Varosy PD, Bao H, et al. Coronary Venous Dissection from Left Ventricular Lead Placement During Cardiac Resynchronization Therapy With Defibrillator Implantation and Associated in-Hospital Adverse Events (from the NCDR ICD Registry). *Am J Cardiol*. 2018 Jan 1;121(1):55-61. doi: 10.1016/j.amjcard.2017.09.019. Epub 2017 Oct 10.
58. **58.** Dev S, Peterson PN, Wang Y, et al. Prevalence, Correlates, and Temporal Trends in Antiarrhythmic Drug Use at Discharge After Implantable Cardioverter Defibrillator Placement (from the National Cardiovascular Data Registry [NCDR]). (*Am J Cardiol* 2014;113:314e320).
59. **59A.** Zusterzeel R, Curtis JP, Caños DA, et al. Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving CRT: Results From the NCDR. *JACC*. 2014; 64(9):887.
60. **59B.** Zusterzeel R, Spatz ES, Curtis JP, et al. Cardiac Resynchronization Therapy in Women Versus Men; Observational Comparative Effectiveness Study From the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes*. 2015;8:S4-S11.

61. **60.** Hsu JC, Varosy PD, Parzynski CS, et al. Procedure timing as a predictor of in-hospital adverse outcomes from implantable cardioverter-defibrillator implantation: Insights from the National Cardiovascular Data Registry. *Am Heart J*. 2015; 169 (1): 45-52.e3.
62. **61.** Borne RT, Peterson PN, Greenlee R, et al. Temporal Trends in Patient Characteristics and Outcomes Among Medicare Beneficiaries Undergoing Primary Prevention Implantable Cardioverter-Defibrillator Placement in the United States, 2006–2010: Results from the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. *CIRC*. 2014; 130 (10): 845-853.
63. **62.** Jordan CP, Freedenberg V, Wang Y, et al. Implant and Clinical Characteristics for Pediatric and Congenital Heart Patients in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. *Circ Arrhythmia Electrophysiol*. 2014;7:1092-1100. Originally published October 6, 2014. doi: 10.1161/CIRCEP.114.001841 <http://circep.ahajournals.org/content/7/6/1092.abstract>.
64. **63.** Sood N, Martin DT, Lampert R, Curtis JP, Parzynski C, Clancy J. Incidence and Predictors of Perioperative Complications with Transvenous Lead Extractions: Real World Experience with NCDR Registry. *Circ EP.Circulation: Arrhythmia and Electrophysiology*. 2018;11:e004768 February 16, 2018 (online) "editors pick".
65. **64.** Hess PL, Greiner MA, Al-Khatib SM, et al. Same-Day Discharge and Risks of Mortality and Readmission After Elective ICD Placement for Primary Prevention. *J Am Coll Cardiol*. 2015;65(9):955-957.
66. **65.** Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, Jessup M, Kapa S, Kremers MS, Lindsay BD, Stevenson LW. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *J Am Coll Cardiol* 2013;61:1318–68.
67. **66.** Dodson JA, Reynolds MR, Bao H, Al-Khatib SM, Peterson ED, Kremers MS, Mirro MJ, Curtis JP, Developing a Risk Model for in-Hospital Adverse Events following ICD Implantation: A Report from the NCDR® Registry, *Journal of the American College of Cardiology* (2013), doi: 10.1016/j.jacc.2013.09.079.
68. **67.** Masoudi FA, Go AS, Magid DJ, et al. Age and Sex Differences in Long-Term Outcomes Following Implantable Cardioverter-Defibrillator Placement in Contemporary Clinical Practice: Findings From the Cardiovascular Research Network. *J Am Heart Assoc*. 2015;4:e002005.
69. **68.** Masoudi FA, Go AS, Magid DJ, et al. Longitudinal Study of Implantable Cardioverter-Defibrillators: Methods and Clinical Characteristics of Patients Receiving Implantable Cardioverter-Defibrillators for Primary Prevention in Contemporary Practice. *Circ Cardiovasc Qual Outcomes*. 2012 Nov; 5(6): e78-85.
70. **69.** Masoudi FM, Mi X, Curtis LH, et al. Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter-Defibrillator Versus Defibrillator Therapy Alone. *Ann Intern Med*. 2014;160:603-611.
71. **70.** Setoguchi S, Warner L, Stewart GC, et al. Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure. *BMJ*. 2014; 348: g2866.
72. **71.** Chen C, S LW, Stewart GC, et al. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure. *BMJ*. 2015;351:h3529.
73. **73.** Gleva MJ, Wang Y, Curtis JP, Berul C, Huddleston CB, Poole JE. Complications Associated with Implantable Cardioverter Defibrillators in Adult Congenital Heart Disease: Insights from the NCDR *Am J Cardiol*. 2017 Aug 8 (online ahead of print).
74. **74.** Green A, Leff B, Wang Y, Spatz ES, Masoudi FA, Peterson PN, Daugherty SL, Matlock DM. Geriatric Conditions in Patients Undergoing Defibrillator Implantation for Prevention of Sudden Cardiac Death:

- Prevalence and Impact on Mortality. *Circ Cardiovasc Qual Outcomes*. 2016 Jan;9(1):23-30.
75. **75.** Khazanie P, Use and Outcomes of Cardiac Resynchronization Therapy among Patients with Heart Failure and Atrial Fibrillation. Submitted title: Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the NCDR ICD Registry. *Circ HF*.
 76. **76.** Kramer DB, Kennedy KF, Spertus JA, et al. Mortality Risk Following Replacement Implantable Cardioverter-Defibrillator Implantation at End of Battery Life: Results from the NCDR® . *Heart Rhythm*. Volume 11, Issue 2 , Pages 216-221, February 2014.
 77. **78.** Ranasinghe I, Parzynski CS, Freeman JV, Dreyer RP, Ross JS, Akar JG, Krumholz HM, Curtis JP. Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study. *Ann Intern Med*. 2016 May 3.
 78. **79.** Friedman D, Singh J, Curtis J, et al. Comparative Effectiveness of Cardiac Resynchronization Therapy with Defibrillator versus Defibrillator Alone in Heart Failure Patients with Moderate to Severe Chronic Kidney Disease. *JACC*. 2015; 65(10S).
 79. **83.** Pokorney SD, Parzynski CS, Daubert JP, Hegland DD, Varosy PD, Curtis JP, Al-Khatib SM. Temporal Trends in and Factors Associated with Use of Single Versus Dual Coil ICD Leads: Data from the NCDR ICD Registry. *JACC: EP Clinical Electrophysiology*. VOL. 3, NO. 6, 2017 Pages 612–619.
 80. **88A.** Akar JG, Bao H, Jones P, et al. Use of Remote Monitoring Is Associated with Lower Risk of Adverse Outcomes Among Patients with Implanted Cardiac Defibrillators. *Circ EP* 2015.
 81. **88B.** Khazanie P, Hellkamp AS, Fonarow GC, et al. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. *J Am Heart Assoc*. 2015;4:e002061.
 82. **93.** Zeitler EP, Wang Y, Dharmarajan K, Anstrom KJ, Peterson ED, Daubert JP, Curtis JP, Al-Khatib SM. Outcomes 1 Year After Implantable Cardioverter-Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads: A Report from the National Cardiovascular Data Registry. *Circ Arrhythm Electrophysiol*. 2016 Jul;9(7).
 83. **94.** Katz DF, Peterson P, Borne RT, Betz J, Al-Khatib SM, MHS, Varosy PD, Wang Y, Hsu J, Hoffmayer K, Kipp R, Hansen CM, Turakhia MP, Masoudi FA. Survival After Secondary Prevention ICD Placement: An Analysis From the NCDR ICD Registry. *JACCCEP*. Volume 3, Issue 1, January 2017, Pages 20-28
EDITORIAL COMMENT FROM A RUSSO AND J POOLE: Secondary Prevention: A Blast from the Past. *JACCCEP*. Volume 3, Issue 1, January 2017, pages 29-32.
 84. **96.** Betz J, Katz DF, Peterson PN, Borne RT, Al-Khatib SN, Wang Y, Malta Hansen C, , McManus D, Mathew J, Masoudi FA. Outcomes of Older Patients Receiving Secondary Prevention ICDs: An Analysis From the NCDR ICD Registry. *JACC*. Volume 69, Issue 3, 24 January 2017, Pages 265–274.
 85. **100.** Echouffo-Tcheugui JB, Masoudi FA, Bao H, Spatz ES, Fonarow GC. Diabetes and Outcomes Of Cardiac Resynchronization with Implantable Cardioverter Defibrillator Therapy in Older Patients with Heart Failure. *Circ Arrhythm Electrophysiol*. 2016 Aug;9(8). pii: e004132.
 86. **101.** Friedman DJ, Parzynski CS, Varosy PD, Prutkin JM, Patton KK, Mithani A, Russo AM, Curtis JP, Al-Khatib SM. Trends and in-hospital outcomes associated with early adoption of the subcutaneous ICD in the US. *JAMA Cardiol*. 2016 Nov 1;1(8):900-911.
 87. **102.** Marzec LN, Peterson PN, Bao H, Curtis JP, Masoudi FA, Varosy PD, Bradley SM. Use of CRT among Eligible Patients Receiving an ICD: Insights from the NCDR ICD Registry. *JAMA Cardiol*. 2017 May 1;2(5):561-565.
 88. **104.** Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ, Shadman R, Anand I, Lund LH, Dahlström U, Sartipy U, Maggioni A, Swedberg K, O'Conner C, Levy WC. Seattle Heart Failure Model and Seattle Proportional Risk Model Together Identify Patients Most Likely to Benefit from Primary Prevention ICDs . *J Am Coll Cardiol*. 2017 May 30;69(21):2606-2618.

89. **110.** Kipp R, Hsu JC, Freeman J, et al. Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry. *Heart Rhythm*. 2017; 0:0.
90. **121.** Friedman DJ, Bao H, Spatz ES, Curtis JP, Daubert JP, Al-Khatib SM. The Association between a Prolonged PR Interval and Outcomes of CRT: a Report from the NCDR. *Circulation*. 2016;134:1617-1628. Originally published October 19, 2016.
91. **123.** Peterson PN, Greenlee RT, Go AS, et al. Inappropriate Shocks with Single versus Dual Chamber ICDs for Primary Prevention: Results from the Cardiovascular Research Network Longitudinal Study of ICDs. *J Am Heart Assoc*. 2017 Nov 9;6(11). pii: e006937. doi: 10.1161/JAHA.117.006937. PMID 29122811.
92. **124.** Bansal N, Szpiro A, Masoudi F, et al. Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators. *Heart (British Cardiac Society)*. 2017;103(7):529-537. doi:10.1136/heartjnl-2016-309842.
93. **125.** Greenlee, RT, Go, A, Peterson, P, et al. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network. *J Am Heart Assoc*. 2018. Volume 7, Issue 7.
94. **127.** Ross JS, Bates J, Parzynski CS, et al. Can machine learning complement traditional medical device surveillance? A case study of dual- chamber implantable cardioverter- defibrillators. *Medical Devices (Auckland, NZ)*. 2017;10:165-188.
95. **128.** Thomas IC, Wang Y, See VY, Minges KE, Curtis JP, Hsu JC. Outcomes following implantable cardioverter-defibrillator generator replacement in patients with recovered left ventricular systolic function: The National Cardiovascular Data Registry. *Heart Rhythm*. 2018 Nov 7. pii: S1547-5271(18)31136-6.
96. **135A.** Kramer DB, Reynolds MR, Normand SL, et al. Hospice Use Following ICD Implantation in Older Patients: Results from the NCDR. *Circulation*. 2016 May 24; 133(21): 2030-2037.
97. **135B.** Kramer DB, Reynolds MR, Normand SL, et al. Nursing Home Utilization following Implantable Cardioverter-Defibrillator Implantation in Older Patients: Results from the NCDR. *J Am Geriatr Soc* 2017 Feb;65(2):340-347. *Journal of Am Geriatrics Society*.
98. **132.** Sandhu A, Bao H, Varosy P, Borne RT, Minges KA, Zipse MM, Marzec L, Peterson P, Masoudi FA, Bradley SM. Use of Cardiac Resynchronization-Defibrillator Therapy in United States Hospitals: Results from the NCDR ICD Registry. *JAMA Cardiol*. June 19, 2019.
99. **137.** Kawata H, Bao H, Curtis JP, et al. Cardiac Resynchronization Defibrillator Therapy for Nonspecific Intraventricular Conduction Delay Versus Right Bundle Branch Block. *Jun 2019, 73 (24) 3082-3099*; DOI: 10.1016/j.jacc.2019.04.025
100. **145.** Desai, NR, Bourdillon, PM, Parzynski, CS, et al. Association of the US Department of Justice Investigation of Implantable Cardioverter-Defibrillators and Devices Not Meeting the Medicare National Coverage Determination 2007-2015. *JAMA* 2018.
101. **146.** Baskar S, Bao H, Minges K, Spar D, Czosek RJ. Characteristics and Outcomes of Pediatric Patients Who Undergo Placement of ICDs - Insights from the NCDR. *Circulation EP*. 2018 Sep;11(9):e006542.
102. **149.** Al-Chekakie MO, Bao H, Jones PW, Stein KM, Marzec L, Varosy PD, Masoudi FA, Curtis JP, Akar JG. Addition of BP and Weight Transmissions to Standard RM of Implantable Defibrillators and its Association with Mortality and Rehospitalization. *CircCQO*. May 2017 Vol 10, Issue 5.
103. **150.** Ambrosy A, Friedman D, Hernandez AF, Fonarow GC, Al-Khatib SM. Is Time from Last Hospitalization for Heart Failure to Placement of a Primary Prevention ICD Associated with Patient Outcomes? *Circulation*. 2018 Dec 11;138(24):2787-2797.
104. **158.** Friedman, D, Parzynski, C, Heist, K, et al. Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: A Report from the National Cardiovascular Data Registry. *CircAHA*. 2018. Volume 137, Issue 19.

105. **193.** Tcheugui JE, Masoudi FA, Bao H, Curtis JP, Heidenreich PA, Fonarow GC. Body Mass Index and Outcomes of Cardiac Resynchronization with Implantable Cardioverter Defibrillator Therapy in Older Patients with Heart Failure.
106. **194.** Bates J, Parzynski CS, Dhruva SS, et al. Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators. *Pharmacoepidemiol Drug Saf.* 2018 Aug;27(8):848-856.
107. **214.** Padala SK, Gunda S, Li S et al. A risk score model for predicting intraprocedural cardiac injury during implantable cardioverter defibrillator implantation: Insights from the National Cardiovascular Data Registry. *J Cardiovasc Electrophysiol.* 2019 Feb;30(2):212-220. Doi:10.1111/jce.13823. Epub 2019 Jan4.

IN PRESS

1. **N/A.** Akar J, et al. Assessing Outcomes and Costs of Remote Patient Monitoring Among Patients with Implanted Cardiac Defibrillators: An Economic Model Based on the PREDICT RM Database. *JAHA.* In Press

PUBLISHED

1. **19.** Jayaram N, Spertus JA, Kennedy KF, et al. Modeling Major Adverse Outcomes of Pediatric and Adult Patients with Congenital Heart Disease Undergoing Cardiac Catheterization: Observations from the NCDR IMPACT Registry. *Circulation*. 2017;136(13).
2. **13.** Boe BA, Zampi JD, Kennedy KF, et al. Acute Success of Balloon Aortic Valvuloplasty in the Current Era: A NCDR Study. *JACC Cardiovasc Interv*. 2017;10(17):1717-1726.
3. **002M.** Martin GR, Beekman RH, Ing FF, et al. The IMPACT registry: Improving Pediatric and Adult Congenital Treatments. *Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual*. 2010;13(1):20-5.
4. **007M.** Moore JW, Vincent RN, Beekman RH, et al. Procedural Results and Safety of Common Interventional Procedures in Congenital Heart Disease: Initial Report from the National Cardiovascular Data Registry. *JACC*. 2014;64(23):2439-2451.
5. **003M.** Vincent RN, Moore J, Beekman III RH, et al. Procedural characteristics and adverse events in diagnostic and interventional catheterizations in pediatric and adult CHD: initial report from the IMPACT Registry. *Cardiology in the Young*. 2015;26(1):70-78.
6. **09M.** Jayaram N, Beekman RH, Benson L, et al. Adjusting for Risk Associated with Pediatric and Congenital Cardiac Catheterization: A Report from the NCDR IMPACT Registry. *Circulation*. 2015;132:1863-1870.
7. **08M.** Holzer R, Beekman R, Benson L, et al. Characteristics and safety of interventions and procedures performed during catheterization of patients with congenital heart disease: early report from the national cardiovascular data registry. *Cardiology in the Young*. 2016;26(6):1202-12.
8. **19M.** Lewis MJ, Kennedy KF, Ginns J, et al. Procedural Success and Adverse Events in Pulmonary Artery Stenting: Insights From the NCDR. *JACC*. 2016;67(11):1327-1335.
9. **13M.** O'Byrne ML, Gillespie MJ, Kennedy KF, et al. The influence of deficient retro-aortic rim on technical success and early adverse events following device closure of secundum atrial septal defects: An Analysis of the IMPACT Registry®. *Catheter Cardiovasc Interv*. 2016;89(1).
10. **18M/8.** Jayaram N, Spertus JA, O'Byrne ML. Relationship between hospital procedure volume and complications following congenital cardiac catheterization: A report from the Improving Pediatric and Adult Congenital Treatment (IMPACT) registry. *Am Heart J*. 2017;183:118-128.
11. **14.** Stefanescu-Schmidt AC, Armstrong A, Kennedy KF, et al. Prediction of adverse events after catheter-based procedures in adolescents and adults with congenital heart disease in the IMPACT registry. *Eur Hear J*. 2017;38(26):2070-2077.

12. **23.** Backes C. Transcatheter Occlusion of the Patent Ductus Arteriosus in 747 Infants <6 kg: Insights from the NCDR IMPACT Registry. JACC Cardiovasc Interv. 2017;10(17):1729-1737.
13. **24.** O'Byrne, M, Kennedy, K, Kanter, J et al. Risk Factors for Major Early Adverse Events Related to Cardiac Catheterization in Children and Young Adults With Pulmonary Hypertension: An Analysis of Data From the IMPACT (Improving Adult and Congenital Treatment) Registry. Journal of the American Heart Association. 2018.

IN PRESS

LAAO Registry

PUBLISHED

1. **0009.** Varosy, P, Masoudi, FA, Reisman, M, et al. Procedural Safety of Watchman Implantation: The US Nested Post Approval Study. JACC 2018

PUBLISHED

1. **1.** Smolderen KG, Sperus JA, Tang F, et al. Treatment Differences by Health Insurance Among Outpatients with Coronary Atery Disease: Insights from the NCDR. *Journal of the American College of Cardiology*. 2013 March 12; 61(10):1069-75.
2. **2.** Chan PS, Maddox TM, Tang F et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE Program). *American Journal of Cardiology*. 2011;108:1136–1140.
3. **3.** Goldsweig AM, Reid KJ, Gosch K, et al. Contemporary Use of Dual Anti-platelet Therapy for Preventing Cardiovascular Events. *Am J Manag Care*. 2014;20(8):659-665.
4. **4.** Spinler SA, Cziraky MH, Tang F et al. Patient Eligibility for Medication Therapy Management Services Within Practices Enrolled in the PINNACLE Registry™. *American Health & Drug Benefits*. 2013;6(7):367-374.
5. **5.** Spinler SA, Cziraky MJ, Willey VJ, et al. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry). *Am J Cardiol* 2015; 116:547-553.
6. **6.** Arnold SV, Spertus JA, Tang F et al.. Statin use in outpatients with obstructive coronary artery disease. *Circulation*. 2011;124:2405-2410.
7. **7.** Oetgen WJ, Mullen JB, Mirro MM. Cardiologists, the PINNACLE Registry, and the "Meaningful Use" of Electronic Health Records. *Journal of the American College of Cardiology*. 2011;57:1560-1563.
8. **8.** May DC, Fiocchi FF, Kehoe K et al. Improving Cardio Care in the Outpatient Setting: Implementing the PINNACLE Registry in a single-specialty practice. *Physician Executive Journal*. 2011;37:38-42.
9. **10.** Erb BD, Allen JM, Chambers L, et al. The PINNACLE Network: Facilitating Quality of Care in Outpatient Cardiovascular Medicine. *US Cardiology*. 2011;8(1):12–5.
10. **11.** Gupta, D, Tang, F, Masoudi, FA, et. Al. Practitioner Gender and Quality of Care in Ambulatory Cardiology Practices: A Report from the NCDR PINNACLE Registry. *J Cardiovasc Nurs*. 2017.
11. **12.** Peterson PN, Chan PS, Spertus JA, et al Practice-level Variation in use of Recommended Medications among Outpatients with Heart Failure: Insights from the NCDR PINNACLE Registry. *Circ Heart Fail*. 2013 Nov; 6(6):1132-8.
12. **13.** Maddox TM, Chan PS, Spertus JA, et al. Variation in CAD Secondary Prevention Prescription among Outpatient Cardiology Practices: Insights from the NCDR®. *JACC*. 2014; 63(6); 539-546.
13. **14.** Marzec LN, Wang J, Shah ND, et al. Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. *J Am Coll Cardiol*. 2017 May 23;69(20):2475-2484.
14. **15.** Oetgen WJ. Duelin' Registries. *Circulation: Cardiovascular Quality and Outcomes*. 2011;4:483-485.
15. **16.** Oetgen WJ, Mullen JB, Mirro MM. Electronic Health Records, the PINNACLE Registry, and Quality Care. *Ar chives of Internal Medicine*. 2011;171(10):953-954.
16. **17.** Subherwal, S, Patel MR, Tang F, et al. Socioeconomic Disparities in Use of Cardioprotective Medications Among Patients with Peripheral Artery Disease—An Analysis of the American College of Cardiology's NCDR PINNACLE Registry®. *JACC*. 2013; (62)1:51-57.
17. **18.** Frederick MA, Singh T, Salami S et al. First Steps: Exploring Use of a Prospective, Office-Based Registry as a Foundation for Quality Improvement in Cardiology Training. *Journal of Graduate Medical Education*. 2013; 5(4): 694-699.
18. **23.** Maddox TM, Chan PS, Spertus JA, et al. Variation in CAD Secondary Prevention Prescription among

- Outpatient Cardiology Practices: Insights from the NCDR®. *JACC*. 2014;63(6):539-546.
19. **24.** Glusenkamp NT, Oetgen WJ, Mullen B. The Million Hearts Initiative-Targeting Key Drivers of Cardiovascular Mortality from a Medical Specialty Society Perspective. *US Cardiology*. 2012;9(1):66–70.
 20. **25.** Hsu JC, Chan PS, Tang F, et al. Differences in Anticoagulant Therapy Prescription in Patients with Paroxysmal Versus Persistent Atrial Fibrillation: Insights from the NCDR® PINNACLE Registry. *Am J Med*. 2015; 128 (6): 654.e1-654.e10.
 21. **26.** Hsu JC, Chan PS, Tang F, Maddox TM, Marcus GM. Oral Anticoagulant Prescription in Atrial Fibrillation Patients with a Low Risk of Thromboembolism: Insights from the NCDR® PINNACLE Registry. *JAMA Intern Med*. 2015;175(6):1062-1065.
 22. **27.** Bandeali SJ, Gosch K, Alam M, et al. Coronary Artery Disease Performance Measures and Statin Use in Patients with Recent Percutaneous Coronary Intervention or Recent Coronary Artery Bypass Grafting (From the NCDR® PINNACLE Registry). *Am J Cardiol*. 2015; 115 (8): 1013-1018.
 23. **28.** Fleming, LM, Jones, P., Chan, PS., Andrei, AC., Maddox, TM., Farmer, SA. Relationship of Provider and Practice Volume to Performance Measure Adherence for Coronary Artery Disease, Heart Failure, and Atrial Fibrillation: Results From the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes*. 2016 Jan;9(1):48-54.
 24. **31.** Virani SS, Maddox TM, Chan PS, et al. Provider Type and Quality of Outpatient Cardiovascular Disease Care, Implications for the Affordable Care Act: Insights from the NCDR®PINNACLE Registry. *Journal of the American College of Cardiology*. 2015;66(16):1803-1812. doi:10.1016/j.jacc.2015.08.017.
 25. **32.** Eapen ZJ, Tang F, Jones PG, et al. Variation in performance measure criteria significantly affects cardiology practice rankings: Insights from the National Cardiovascular Data Registry's Practice Innovation and Clinical Excellence Registry. *Am Heart J*. 2015 Jun; 169 (6): 847-853.
 26. **33.** Hira RS, Kennedy K, Nambi V, et al. Frequency and Practice-Level Variation in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease: Insights From the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence Registry. *J Am Coll Cardiol*. 2015; 65(2): 111-121.
 27. **34.** Hira RS, Kennedy K, Jneid H, et al. Frequency and Practice-Level Variation in Inappropriate and Nonrecommended Prasugrel Prescribing: Insights From the NCDR PINNACLE Registry. *JACC*. 2014; 63(25_PA): 2876-7.
 28. **37.** Hsu JC, Maddox TM, Kennedy K, Katz DF, Marzec LN, Lubitz SA, Gehi AK, Turakhia MP, Marcus GM. Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. *J Am Coll Cardiol*.
 29. **38.** Hsu JC, Maddox TM, Kennedy K, et al; Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke; 2016-6-28; 67; 25.
 30. **60.** Wasfy JH, Kennedy KF, Chen JS, Ferris TG, Maddox TM, Yeh RW. Practice Variation in Triple Therapy for Patients With Both Atrial Fibrillation and Coronary Artery Disease: Insights From the ACC's National Cardiovascular Data Registry. *JACCCEP*. 2016;2(1):36-43. doi:10.1016/j.jacep.2015.08.010.
 31. **64.** Maddox TM, Borden WB, Tang F, et al. Implications of the 2013 ACC/AHA Cholesterol Guidelines for Adults in Contemporary Cardiovascular Practice: Insights From the NCDR PINNACLE Registry. *J Am Coll Cardiol*. 2014; 64(21): 2183-2192. doi:10.1016/j.jacc.2014.08.041.
 32. **65.** Borden WB, Maddox TM, Tang F, et al. Impact of the 2014 Expert Panel Recommendations for Management of High Blood Pressure on Contemporary Cardiovascular Practice: Insights From the National Cardiovascular Data Registry PINNACLE Registry. *J Am Coll Cardiol*. 2014; 64(21): 2196-2203. doi:10.1016/j.jacc.2014.09.022.
 33. **71.** Gehi AK, Doros G, Glorioso TJ, et al. Factors associated with rhythm control treatment decisions in patients with atrial fibrillation-Insights from the NCDR PINNACLE registry. *Am Heart J*. 2017

May;187:88-97.

34. **72.** Katz DF, Maddox TM, Turakhia M, et al. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk Assessment Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry. *Circulation: Cardiovascular Quality and Outcomes*. 2017;10:e003476.
35. **73.** Contreras, J.P., Hong, K.N., Castillo, J., Marzec, L.N., Hsu, J.C., Cannon, C.P., Yang, S. and Maddox, T.M., 2019. Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. *Clinical cardiology*, 42(3), pp.339-345.
36. **75.** Thompson, LE, Maddox, TM, Lei, L, et al. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report from the NCDR PINNACLE Registry. *JAHA*. 2017.
37. **76.** Lubitz, SA, Khurshid, S, Lu-Chen, W, et al. Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. *AHJ* 2018.
38. **77.** Yong, C, Liu, Y, Apruzzese, P, et al. Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the ACC NCDR PINNACLE Registry. *AHJ* 2018.
39. **86.** Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. *JAMA Cardiol*. 2017 Apr 1;2(4):361-369.
40. **87.** Pokharel Y, Gosch K, Nambi V, et al. Frequency and Practice Level Variation in Statin Use Among Patients with Diabetes: Insights from the ACC NCDR® PINNACLE Registry. *Journal of the American College of Cardiology*. 2016;68(12):1368-1369. doi:10.1016/j.jacc.2016.06.048.
41. **90.** Maddox TM, Tang F, Downs JR, et al. Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project. *JAMA Internal Medicine*. 2017;177(6):887-889. doi:10.1001/jamainternmed.2017.0754.
42. **92.** Allen, Larry & Tang, Fengming & Jones, Philip & Breeding, Tracie & Ponirakis, Angelo & J. Turner, Stuart. (2018). Signs, symptoms, and treatment patterns across serial ambulatory cardiology visits in patients with heart failure: Insights from the NCDR PINNACLE® registry. *BMC Cardiovascular Disorders*. 18. 10.1186/s12872-018-0808-2.
43. **93.** Hess, P, Kennedy, K, Cowherd, Mm et al. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. *Am Heart J*. 2018. Volume 195:151-152. doi: 10.1016/j.ahj.2017.09.004.
44. **94.** Mathew JS, Marzec LN, Kennedy KF, Jones PG, Varosy PD, Masoudi FA, Maddox TM, Allen LA. Atrial Fibrillation in Heart Failure US Ambulatory Cardiology Practices and the Potential for Uptake of Catheter Ablation: An NCDR Research to Practice (R2P) Project, *J Am Heart Assoc*. 2017.
45. **103.** Sardana M, Tang Y, Magnani JW, et al. Provider-Level Variation in Smoking Cessation Assistance Provided in the Cardiology Clinics: Insights From the NCDR PINNACLE Registry. *J Am Heart Assoc*. 2019 Jul 2;8(13):e011412. doi: 10.1161/JAHA.118.011307. Epub 2019 Jun 28.
46. **130.** Bradley SM, Hess GP, Stewart P, et al. Implications of the PEGASUS-TIMI 54 trial for US clinical practice. *Open Heart*. 2017;4(1):e000580. doi:10.1136/openhrt-2016-000580.
47. **156.** Figueroa JF, Blumenthal DM, Feyman Y, Frakt AB, Turchin A, Doros G, Gao Q, Song Y, Joynt Maddox KE. Differences in Management of Coronary Artery Disease in Patients With Medicare Advantage vs Traditional Fee-for-Service Medicare Among Cardiology Practices. *JAMA Cardiol*. 2019 Feb 20. [Epub] PMID: 30785590.
48. **177.** Virani, Salim, et al. Frequency and Practice-Level Variation in Lipid Lowering Medication Use Among Patients with Very High LDL-C Levels: Insights from the NCDR®PINNACLE Registry.
49. **182.** Ibrahim NE, Song Y, Cannon CP, et al. Heart failure with mid-range ejection fraction:

characterization of patients from the PINNACLE Registry®. ESC Heart Fail. 2019 Aug;6(4):784-792. doi: 10.1002/ehf2.12455. Epub 2019 Jul 3.

50. **N/A.** Chan P, Oetgen W, Spertus J, et al. The Improving Continuous Cardiac Care (IC3) Program and Outpatient Quality Improvement. The American Journal of Medicine. 2010;123(3): 217- 219.
51. **N/A.** Chan P.S., Oetgen W.J., Buchanan D.; Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. J Am Coll Cardiol. 56 2010:8-14.

IN PRESS

1. **181.** Ibrahim J, et al. Use of Sacubitril/Valsartan in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction following its Addition to Clinical Practice Guidelines: An Analysis from the American College of Cardiology's (ACC) National Cardiovascular Data Reg- Novartis RPA #2. ESC-HF. In Press

PVI Registry

PUBLISHED

1. **9.** Bhardwaj, B, Spertus JA, Kennedy, KF, et al. Bleeding Complications in Lower-Extremity Peripheral Vascular Interventions: Insights from the NCDR PVI Registry. JACC CI 2019.
2. **13.** Goldsweig, AM, Kennedy, KF, Abbott, JD, et al. Patient Radiation Dosage During Lower Extremity Endovascular Intervention. JACC CI. March 2019

IN PRESS

1. Jones, W. et al. The American College of Cardiology Peripheral Vascular Intervention Registry: Methods and Design. AHJ

TVT Registry

PUBLISHED

1. **8.** Holmes DR, Brennan JM, Rumsfeld JS, et al. Clinical Outcomes at 1 Year Following Transcatheter Aortic Valve Replacement. JAMA. 2015;313(10):1019-1028.
2. **Editorial.** Rumsfeld JS, Holmes DR, Stough WG, et al. Insights From the Early Experience of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. JACC Cardiovasc Interv. 2015;8(3):377-381.
3. **Editorial.** Mack MJ, Holmes DR. Rational Dispersion for the Introduction of Transcatheter Valve Therapy. JAMA. 2011;306(19):2149-2150.
4. **Editorial.** Carroll JD, Shuren J, Jensen ST, et al. Transcatheter Valve Therapy Registry Is a Model for Medical Device Innovation and Surveillance. Health Affairs. 2015;34(2):328-334.
5. **05T/3.** Brennan JM, Holmes DR, Sherwood MW, et al. The association of transcatheter aortic valve replacement availability and hospital aortic valve replacement volume and mortality in the United States. Annals of Thoracic Surgery. 2014;98(6):2016-22
6. **Editorial.** Carroll JD, Edwards FH, Marinac-Dabic D, et al. The STS-ACC Transcatheter Valve Therapy National Registry: A New Partnership and Infrastructure for the Introduction and Surveillance of Medical Devices and Therapies. JACC. 2013;62(11):1026-1034.
7. **04T/2.** Mack MJ, Brennan JM, Brindis R. Outcomes Following Transcatheter Aortic Valve Replacement in the United States. JAMA. 2013;310(19):2069-2077.
8. **Editorial.** Sedrakyan A, Marinac-Dabic D, Holmes DR. The international registry infrastructure for cardiovascular device evaluation and surveillance. JAMA. 2013;310(3):257-9
9. **44/50T.** Thourani VH, Jensen HA, Babaliaros V, et al. Transapical and Transaortic Transcatheter Aortic Valve Replacement in the United States. Annals of Thoracic Surgery. 2015;100:1718–27.

10. **74 /25T.** Suri RM, Gulack BC, Brennan JM, et al. Outcomes of Patients with Severe Chronic Lung Disease Who Are Undergoing Transcatheter Aortic Valve Replacement. *Annals of Thoracic Surgery*. Available online 29 August 2015.
11. **107.** Holmes DR, Nishimura RA, Grover FL, et al. Annual Outcomes with Transcatheter Valve Therapy: From the STS/ACC TVT Registry. *Annals of Thoracic Surgery*. 2016;101(2):789-800.
12. **33.** Arnold SV, Spertus JA, Vemulapalli S, et al. Association of Patient-Reported Health Status with Long-Term Mortality After Transcatheter Aortic Valve Replacement: Report From the STS/ACC TVT Registry. *Circ Interv*. 2015;8(12).
13. **109.** Sorajja P, Mack M, Vemulapalli S, et al. Initial Experience With Commercial Transcatheter Mitral Valve Repair in the United States. *JACC*. 2016; 67(10).
14. **108.** Edwards FH, Cohen DJ, O'Brien SM, et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality After Transcatheter Aortic Valve Replacement. *JAMA Cardiol*. 2016;1(1):46-52.
15. **72.** Arsalan M, Szerlip M, Vemulapalli S, et al. Should Transcatheter Aortic Valve Replacement Be Performed in Nonagenarians? Insights From the STS/ACC TVT Registry. *JACC*. 2016;67(10).
16. **27.** Alfredsson J, Stebbins A, Brennan JM, et al. Gait Speed Predicts 30-Day Mortality After Transcatheter Aortic Valve Replacement: Results from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. *Circulation*. 2016;133.
17. **37.** Baron SJ, Arnold SV, Herrmann HC, et al. Impact of Ejection Fraction and Aortic Valve Gradient on Outcomes of Transcatheter Aortic Valve Replacement. *JACC*. 2016;67(20):2349-2358.
18. **5.** O'Brien SM, Cohen DJ, Rumsfeld JS, et al. Variation in Hospital Risk-Adjusted Mortality Rates Following Transcatheter Aortic Valve Replacement in the United States: A Report from the STS/ACC TVT Registry. *Circ Cardiovasc Qual Outcomes*. 2016;9:560-565.
19. **105.** Fadahunsi OA, Olowoyeye A, Ukaigwe A, et al. Incidence, Predictors, and Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement: Analysis from STS/ACC TVT Registry. *JACC Cardiovasc Interv*. 2016;9(21):2189-2199.
20. **90.** Chandrasekhar J, Dangas G, Yu J, et al. Sex-Based Differences in Outcomes with Transcatheter Aortic Valve Therapy. *JACC*. 2016;68(25):2733-44.
21. **169.** Arnold SV, Spertus JA, Vemulapalli S, et al. Quality-of-Life Outcomes After Transcatheter Aortic Valve Replacement in an Unselected Population: A Report from the STS/ACC TVT Registry. *JAMA Cardiol*. 2017;2(4):409-416.
22. **130.** Dodson JA, Williams MR, Cohen DJ, et al. Home Practice of Direct-Home Discharge and 30-Day Readmission After Transcatheter Aortic Valve Replacement in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry. *JAHA*. 2017;6(8).

23. **34.** Hira RS, Vemulapalli S, Li Z, et al. Trends and Outcomes of Off-label Use of Transcatheter Aortic Valve Replacement Insights from the NCDR STS/ACC TVT Registry. *JAMA Cardiol.* 2017;2(8):846-854.
24. **106.** Carroll JD, Vemulapalli S, Dai D, et al. Procedural Experience for Transcatheter Aortic Valve Replacement and Relation to Outcomes. *JACC.* 2017;70(1).
25. **269.** Brennan MJ, Thomas L, Cohen DJ, et al. Transcatheter Versus Surgical Aortic Valve Replacement. *JACC.* 2017;70(4).
26. **245.** Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with Transcatheter Mitral Valve Repair in the United States: An STS/ACC TVT Registry Report. *JACC.* 2017;70(19):2315-2327.
27. **119.** Hyman MC, Vemulapalli S, Szeto WY, et al. Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Insights from the NDCR STS/ACC TVT Registry. *Circulation.* 2017;136(22).
28. **42.** Mavromatis K, Thourani VH, Stebbins A, et al. Transcatheter Aortic Valve Replacement in Patients with Aortic Stenosis and Mitral Regurgitation. *Annals of Thoracic Surgery.* 2017;104(6).
29. **243.** Sorajja P, Kodali S, Reardon MJ, et al. Outcomes for the Commercial Use of Self-Expanding Prostheses in Transcatheter Aortic Valve Replacement: A Report From the STS/ACC TVT Registry. *JACC Cardiovasc Interv.* 2017;10(20):2090-2098.
30. **190.** Fanaroff AC, Manandhar P, Holmes DR, et al. Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes. *Circ Interv.* 2017;10(10).
31. **174.** Abramowitz Y, Vemulapalli S, Chakravarty T, et al. Clinical Impact of Diabetes Mellitus on Outcomes After Transcatheter Aortic Valve Replacement: Insights from the STS/ACC TVT Registry. *Circ Interv.* 2017;10(11).
32. **180.** Hansen, JW, Foy, A, Yadav, P, et al. Death and Dialysis After Transcatheter Aortic Valve Replacement. An Analysis of the STS/ACC TVT Registry. *JACC Cardiovasc Interv.* Sept. 2017
33. **254.** Kolte, D., Khera, S., Vemulapalli, S. Outcomes Following Urgent/Emergent Transcatheter Aortic Valve Replacement: Insights from the STS/ACC TVT Registry. *JACC.* March 2018
34. **140.** McCarthy, FH, Vemulapalli, S, Zhuokai, L, et al. The Association of Tricuspid Regurgitation With Transcatheter Aortic Valve Replacement Outcomes: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. *ATS.* March 2018
35. **153.** Joseph, L, Bashir, M, Xiang, Q, et al. Prevalence and Outcomes of Mitral Stenosis in Patients Undergoing Transcatheter Aortic Valve Replacement: Findings From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry. *JACC Cardiovasc Interv.* April 2018
36. **58.** Tuzcu, EM, Kapadia, SR, Vemulapalli, S, et al. Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses; The STS/ACC Registry. *JACC.* 2018

37. **191.** Kochar, A, Li, Z, Harrison, JK, et al. Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing Transcatheter Aortic Valve Replacement. *Circ Cardiovasc Interv.* 2018
38. **155.** Vora AN, Dai D, Matsuoka R, et al. Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis from the STS/ACC TVT Registry. *JACC CI* 2018
39. **270.** Arnold SV, O'Brien SM, Vemulapalli S, et al. Inclusion of Functional Status Measures in the Risk Adjustment of 30-Day Mortality After Transcatheter Aortic Valve Replacement. *JACC CI* 2018
40. **7.** Sherwood, M. et al. Practice patterns and outcomes associated with differential use of antithrombotics after TAVR: Insights from the STS/ACC TVT Registry®. *AHJ* 201
41. **264.** Herrmann, HC, Daneshvar, SA, Fonarow, GC et al. Prosthesis–Patient Mismatch in 62,125 Patients Following Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry. *JACC* 2018
42. **224.** Inohara, T, Manandhar, P, Kosinski, AS, et al. Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients with Transcatheter Aortic Valve Replacement. *JAMA* 2018.
43. **272.** Arnold, SV, Li, Z, Vemulapalli, S, et al. Association of Transcatheter Mitral Valve Repair with Quality of Life Outcomes at 30 days and 1 year: Analysis of the Transcatheter Valve Therapy Registry. *JAMA Card* 2018.
44. **268.** Thourani, VH, O'Brien, SM, Kelly, JJ, et al. Development and Application of Risk Prediction Model for In-Hospital Stroke after Transcatheter Aortic Valve Replacement: A Report From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. *Ann Thorac Surg* 2019
45. **301.** Varshney, AS, Manandhar, P, Vemulapalli, S, et al. Left Ventricular Hypertrophy Does Not Affect 1-Year Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. *JACC CI* 2019
46. **197.** Wayangankar, S.A., Elgendy, I.Y., Xiang, Q., et al. Length of Stay After Transfemoral Transcatheter Aortic Valve Replacement An Analysis of the Society of Thoracic Surgeons/ American College of Cardiology Transcatheter Valve Therapy Registry. *JACC CI* 2019
47. **249.** Shah, B, Villablanca, P, Vemulapalli, S, et al. Outcomes After Transcatheter Mitral Valve Repair in Patients With Renal Disease Insights From the Society of Thoracic Surgeons/American College of Cardiology National Cardiovascular Data Registry Transcatheter Valve Therapy Registry. *Circ CI* 2019
48. **215.** Arora, S.A., Vemulapalli, S, Stebbins, A, et al. The Prevalence and Impact of Atrial Fibrillation on 1-Year Outcomes in Patients Undergoing Transcatheter Mitral Valve Repair: Results From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. *JACC CI* 2019
49. **133.** Vemulapalli, S, Dai, D, Hammill, BG, et al. Hospital Resource Utilization Before and After Transcatheter Aortic Valve Replacement: The STS/ACC TVT Registry. *JACC* 2019.

50. **263.** Huded CP, Tuzcu EM, Kishnaswamy A, et al. Association Between Transcatheter Aortic Valve Replacement and Early Postprocedural Stroke. JAMA Card 2019
51. **332.** Sanchez CE, Hermiller JB, Pinto DS, et al. Predictors and risk calculator of early unplanned hospital readmission following contemporary self-expanding transcatheter aortic valve replacement from the STS/ACC TVT-registry. Cardiovascular Revascularization Medicine 2019
52. **291.** Alkhouli, M, Holmes DR, Carroll, JD et al. Racial Disparities in the Utilization and Outcomes of TAVR: TVT Registry Report. JACC CI 2019
53. **57.** Szerlip, M, Zajarias, A, Vemalapalli, S, et al. Transcatheter Aortic Valve Replacement in Patients with End-Stage Renal Disease. JACC 2019
54. **453.** Dahle, TG, Kaneko, T, McCabe, JM. Outcomes Following Subclavian and Axillary Artery Access for Transcatheter Aortic Valve Replacement: STS/ACC TVT Registry Report. JACC CI 2019
55. **211.** Chhatrwalla, Ak, Vemulapalli, S, Holmes, DR, et al. Institutional Experience With Transcatheter Mitral Valve Repair and Clinical Outcomes. JACC CI 2019

IN PRESS

1. **156.** Pineda, AP et al. Incidence and Outcomes of Patients Requiring Surgical Bail-Out during Transcatheter Aortic Valve Replacement from the NCDR® STS/ACC TVT Registry. JACC CI
2. **127.** Anwaruddin, S et al. A Characterization of the Incidence and Predictors of Paravalvular Regurgitation (PVL) and its Impact on Outcomes: A Study of the STS/ACC Transcatheter Valve Therapy (TVT) Database. AJC
3. **267.** Kiani, S et al. The Effect of Age and Frailty on Survival in Patients Undergoing TAVR. JACC CI
4. **236.** Thourani, V et al. Analysis of transcatheter aortic valve replacement in those with or without a previous mitral valve prosthesis. ATS
5. **186.** Wang, A et al. Effects of Fragmentation of Post-Procedural Care on Outcomes after TAVR. AJC
6. **244.** Qintar, M et al. Effect of smoking on clinical and health status outcomes after transcatheter aortic valve replacement (TAVR). JAHA
7. **194.** Wang, A et al. Incidence and Risk Factors of Aborted Procedures and Emergent Conversion to Surgery During Elective TAVR. JACC CI.

NCDR-wide Publications

PUBLISHED

2. **01-N.** Anderson HV, Weintraub WS, Radford MJ, et al. Standardized Cardiovascular Data for Clinical Research, Registries, and Patient Care A Report from the Data Standards Workgroup of the National Cardiovascular Research Infrastructure Project. A collaboration of the Duke Clinical Research Institute and the American College of Cardiology - National Cardiovascular Data Registry. JACC. 2013;61:1835-46.
3. **02N-B.** Messenger JC, Ho KL, Young CH, et al. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: The NCDR Data Quality Program in 2012. JACC. 2012;60(16):1484-8.
4. **3-N.** Masoudi FM, Ponirakis A, Yeh RW, et al. Cardiovascular Care Facts: A Report from the NCDR - 2011. JACC. 2013;62(21):1931-1947.

IN PRESS